CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | organometalloidal compound |
|
Accession: | CHEBI:143084
|
browse the term
|
Definition: | A compound having bonds between one or more metalloid atoms and one or more carbon atoms of an organyl group. |
Synonyms: | related_synonym: | organometalloidal; organometalloidal compounds; organometalloidals |
| xref: | PMID:15246002; PMID:17741021; PMID:8403081; PMID:908316 |
|
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
decreases expression multiple interactions |
EXP |
Arsanilic Acid results in decreased expression of BDNF mRNA; Arsanilic Acid results in decreased expression of BDNF protein Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of BDNF mRNA]; Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of BDNF protein]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of BDNF mRNA]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of BDNF protein]] |
CTD |
PMID:30628712 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Casp3 |
caspase 3 |
increases activity increases cleavage multiple interactions increases expression |
EXP |
Arsanilic Acid results in increased activity of CASP3 protein Arsanilic Acid results in increased cleavage of CASP3 protein Dexamethasone inhibits the reaction [Arsanilic Acid results in increased cleavage of CASP3 protein]; Dexamethasone inhibits the reaction [Arsanilic Acid results in increased expression of CASP3 mRNA]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in increased cleavage of CASP3 protein]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in increased expression of CASP3 mRNA]] |
CTD |
PMID:23848144 PMID:30628712 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases activity |
EXP |
Arsanilic Acid results in increased activity of CASP9 protein |
CTD |
PMID:23848144 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
decreases expression multiple interactions |
EXP |
Arsanilic Acid results in decreased expression of NTRK2 mRNA; Arsanilic Acid results in decreased expression of NTRK2 protein Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of NTRK2 mRNA]; Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of NTRK2 protein]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of NTRK2 mRNA]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of NTRK2 protein]] |
CTD |
PMID:30628712 |
|
NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136
|
|
G |
Slc12a5 |
solute carrier family 12 member 5 |
decreases expression multiple interactions |
EXP |
Arsanilic Acid results in decreased expression of SLC12A5 mRNA; Arsanilic Acid results in decreased expression of SLC12A5 protein Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of SLC12A5 mRNA]; Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of SLC12A5 protein]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of SLC12A5 mRNA]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of SLC12A5 protein]] |
CTD |
PMID:30628712 |
|
NCBI chr 3:153,696,522...153,735,801
Ensembl chr 3:153,696,517...153,735,765
|
|
|
G |
A2m |
alpha-2-macroglobulin |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of A2ML1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
|
|
G |
Aacs |
acetoacetyl-CoA synthetase |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of AACS mRNA |
CTD |
PMID:34876320 |
|
NCBI chr12:31,113,098...31,156,411
Ensembl chr12:31,113,098...31,160,954
|
|
G |
Aard |
alanine and arginine rich domain containing protein |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of AARD mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:83,364,478...83,369,319
Ensembl chr 7:83,364,204...83,369,317
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression decreases expression |
EXP |
Cacodylic Acid results in increased expression of ABCB1A mRNA; Cacodylic Acid results in increased expression of ABCB1A protein Cacodylic Acid results in decreased expression of ABCB1A mRNA |
CTD |
PMID:16436460 PMID:17720352 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases expression affects transport decreases response to substance increases transport |
EXP ISO |
Cacodylic Acid results in increased expression of ABCC1 mRNA; Cacodylic Acid results in increased expression of ABCC1 protein ABCC1 protein modified form affects the transport of Cacodylic Acid ABCC1 protein results in decreased susceptibility to Cacodylic Acid ABCC1 protein results in increased transport of Cacodylic Acid |
CTD |
PMID:16436460 PMID:29752257 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of ABCC2 mRNA; Cacodylic Acid results in increased expression of ABCC2 protein |
CTD |
PMID:16436460 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of ABCC3 mRNA; Cacodylic Acid results in increased expression of ABCC3 protein |
CTD |
PMID:16436460 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases transport affects export increases export |
ISO |
ABCC4 protein results in increased transport of Cacodylic Acid ABCC4 gene SNP affects the export of Cacodylic Acid ABCC4 protein results in increased export of Cacodylic Acid |
CTD |
PMID:24870404 PMID:25752797 PMID:27659809 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Acap1 |
ArfGAP with coiled-coil, ankyrin repeat and PH domains 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ACAP1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:54,605,323...54,619,472
Ensembl chr10:54,605,323...54,619,472
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
Cacodylic Acid results in decreased activity of ACHE protein |
CTD |
PMID:21440049 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ACOT1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163
|
|
G |
Acot12 |
acyl-CoA thioesterase 12 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ACOT12 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:22,986,867...23,027,538
Ensembl chr 2:22,986,626...23,027,536
|
|
G |
Acox2 |
acyl-CoA oxidase 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ACOX2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr15:16,660,584...16,692,160
Ensembl chr15:16,660,272...16,692,160
|
|
G |
Acrbp |
acrosin binding protein |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ACRBP mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 4:157,851,149...157,864,211
Ensembl chr 4:157,841,841...157,864,213
|
|
G |
Actn1 |
actinin, alpha 1 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of ACTN1 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251
|
|
G |
Adamts4 |
ADAM metallopeptidase with thrombospondin type 1 motif, 4 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ADAMTS4 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065
|
|
G |
Adamts6 |
ADAM metallopeptidase with thrombospondin type 1 motif, 6 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ADAMTS6 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:35,421,483...35,633,305
Ensembl chr 2:35,421,510...35,633,298
|
|
G |
Adgrg1 |
adhesion G protein-coupled receptor G1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ADGRG1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108
|
|
G |
Adm |
adrenomedullin |
increases expression multiple interactions |
ISO |
Cacodylic Acid results in increased expression of ADM mRNA [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ADM mRNA |
CTD |
PMID:32052077 PMID:34876320 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Adra2b |
adrenoceptor alpha 2B |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ADRA2B mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 3:114,585,174...114,589,220
Ensembl chr 3:114,585,169...114,589,355
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ADRB1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:255,772,217...255,773,617
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ADRB2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Aff3 |
AF4/FMR2 family, member 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of AFF3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 9:40,399,109...40,856,716
Ensembl chr 9:40,404,375...40,857,247
|
|
G |
Afp |
alpha-fetoprotein |
increases expression |
ISO |
Cacodylic Acid results in increased expression of AFP mRNA |
CTD |
PMID:15345372 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Agr3 |
anterior gradient 3, protein disulphide isomerase family member |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of AGR3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 6:52,643,391...52,666,638
Ensembl chr 6:52,643,391...52,666,638
|
|
G |
Agtrap |
angiotensin II receptor-associated protein |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of AGTRAP mRNA |
CTD |
PMID:22246474 |
|
NCBI chr 5:158,507,427...158,519,036
Ensembl chr 5:158,508,749...158,519,036
|
|
G |
Ahdc1 |
AT hook, DNA binding motif, containing 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of AHDC1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:145,228,228...145,294,170
Ensembl chr 5:145,228,227...145,294,145
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
AHR mutant form inhibits the reaction [Cacodylic Acid results in increased expression of CYP1A1 protein]; Cacodylic Acid results in decreased expression of and affects the localization of AHR protein Cacodylic Acid affects the reaction [[Tetrachlorodibenzodioxin results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA]; Cacodylic Acid affects the reaction [[Tetrachlorodibenzodioxin results in increased activity of AHR protein] which results in increased expression of CYP1A1 protein] |
CTD |
PMID:24161444 PMID:28134025 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ahsg |
alpha-2-HS-glycoprotein |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of AHSG mRNA |
CTD |
PMID:32052077 |
|
NCBI chr11:78,117,903...78,145,956
Ensembl chr11:78,117,918...78,145,999
|
|
G |
Aire |
autoimmune regulator |
multiple interactions |
ISO |
[Arsenic results in increased abundance of Cacodylic Acid] which affects the expression of AIRE mRNA |
CTD |
PMID:28793237 |
|
NCBI chr20:10,636,058...10,651,060
Ensembl chr20:10,636,123...10,651,060
|
|
G |
Ak4 |
adenylate kinase 4 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of AK4 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:116,039,222...116,099,064
Ensembl chr 5:116,039,616...116,098,618
|
|
G |
Akr7a2 |
aldo-keto reductase family 7, member A2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of AKR7A5 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO EXP |
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of AKT1 mRNA Cacodylic Acid results in increased expression of and results in increased phosphorylation of AKT1 protein |
CTD |
PMID:23192986 PMID:32890875 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of ALB mRNA |
CTD |
PMID:32052077 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of ALDH1A1 protein |
CTD |
PMID:33211169 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ALDOC mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Alpk1 |
alpha-kinase 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ALPK1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:216,126,939...216,247,180
Ensembl chr 2:216,128,825...216,247,157
|
|
G |
Angptl7 |
angiopoietin like 7 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ANGPTL7 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:158,932,094...158,937,597
Ensembl chr 5:158,932,794...158,937,324
|
|
G |
Ankrd1 |
ankyrin repeat domain 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ANKRD1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:233,815,851...233,834,891
Ensembl chr 1:233,815,851...233,834,919
|
|
G |
Ankrd40cl |
ANKRD40 C-terminal like |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ANKRD40CL mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:79,227,791...79,236,365
Ensembl chr10:79,231,211...79,235,324
|
|
G |
Anxa8 |
annexin A8 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ANXA8 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr16:9,397,144...9,412,072
Ensembl chr16:9,397,113...9,412,043
|
|
G |
Aoc3 |
amine oxidase, copper containing 3 |
multiple interactions increases expression |
ISO |
OGG1 protein inhibits the reaction [Cacodylic Acid results in increased expression of AOC3 mRNA] |
CTD |
PMID:17441966 |
|
NCBI chr10:86,272,757...86,280,702
|
|
G |
Apoe |
apolipoprotein E |
affects response to substance multiple interactions |
ISO |
APOE protein affects the susceptibility to Cacodylic Acid AS3MT protein affects the reaction [APOE protein affects the susceptibility to Cacodylic Acid] |
CTD |
PMID:28728140 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Apol9a |
apolipoprotein L 9a |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of APOL9A mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:109,140,871...109,149,799
Ensembl chr 7:109,140,871...109,147,649
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions increases expression |
ISO |
Cacodylic Acid results in increased cleavage of and affects the secretion of APP protein mutant form; Cacodylic Acid results in increased expression of and affects the localization of APP protein mutant form Cacodylic Acid results in increased expression of APP protein |
CTD |
PMID:21440049 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp7 |
aquaporin 7 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of AQP7 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr 5:56,171,649...56,186,642
Ensembl chr 5:56,172,519...56,186,642
|
|
G |
Areg |
amphiregulin |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of AREG mRNA |
CTD |
PMID:34876320 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Arf6 |
ADP-ribosylation factor 6 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of ARF6 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 6:87,853,742...87,854,890
Ensembl chr 6:87,840,142...87,874,114
|
|
G |
Arhgap15 |
Rho GTPase activating protein 15 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGAP15 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 3:27,989,368...28,592,722
Ensembl chr 3:27,989,633...28,600,265
|
|
G |
Arhgap21 |
Rho GTPase activating protein 21 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of ARHGAP21 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr17:83,348,673...83,472,202
Ensembl chr17:83,348,673...83,472,444
|
|
G |
Arhgap25 |
Rho GTPase activating protein 25 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGAP25 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 4:119,896,844...119,974,982
Ensembl chr 4:119,896,844...119,974,982
|
|
G |
Arhgap30 |
Rho GTPase activating protein 30 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGAP30 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr13:83,822,290...83,843,634
Ensembl chr13:83,822,283...83,854,885
|
|
G |
Arhgap45 |
Rho GTPase activating protein 45 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGAP45 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:9,674,873...9,690,286
Ensembl chr 7:9,674,897...9,690,268
|
|
G |
Arhgap8 |
Rho GTPase activating protein 8 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGAP8 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:115,842,223...115,902,094
Ensembl chr 7:115,850,654...115,902,093
|
|
G |
Arhgdib |
Rho GDP dissociation inhibitor beta |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGDIB mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658
|
|
G |
Arhgef38 |
Rho guanine nucleotide exchange factor 38 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ARHGEF38 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:221,610,212...221,739,841
Ensembl chr 2:221,613,070...221,740,079
|
|
G |
Arl5c |
ADP-ribosylation factor like GTPase 5C |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARL5C mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:82,985,213...82,993,425
Ensembl chr10:82,985,216...82,992,002
|
|
G |
Arl9 |
ADP-ribosylation factor like GTPase 9 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ARL9 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr14:31,157,585...31,166,803
Ensembl chr14:31,157,586...31,166,699
|
|
G |
Arntl |
aryl hydrocarbon receptor nuclear translocator-like |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ARNTL mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
|
|
G |
As3mt |
arsenite methyltransferase |
multiple interactions |
ISO |
[AS3MT gene polymorphism affects the metabolism of Arsenic] which affects the abundance of Cacodylic Acid; [AS3MT gene polymorphism affects the susceptibility to Arsenic] which results in increased abundance of Cacodylic Acid; [AS3MT protein polymorphism results in increased metabolism of arsenite] which results in increased chemical synthesis of Cacodylic Acid; [AS3MT protein polymorphism results in increased metabolism of monomethylarsonic acid] which results in increased chemical synthesis of Cacodylic Acid; [AS3MT protein results in increased metabolism of arsenite] which results in increased chemical synthesis of Cacodylic Acid; [AS3MT protein results in increased metabolism of monomethylarsonic acid] which results in increased chemical synthesis of Cacodylic Acid AS3MT protein affects the reaction [APOE protein affects the susceptibility to Cacodylic Acid] |
CTD |
PMID:22868225 PMID:24845704 PMID:28728140 PMID:32650499 |
|
NCBI chr 1:245,595,939...245,628,921
Ensembl chr 1:245,596,108...245,627,872
|
|
G |
Asb14 |
ankyrin repeat and SOCS box-containing 14 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ASB14 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr16:2,095,567...2,123,259
Ensembl chr16:2,095,644...2,115,135
|
|
G |
Asb4 |
ankyrin repeat and SOCS box-containing 4 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ASB4 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 4:33,506,992...33,544,630
Ensembl chr 4:33,506,992...33,544,630
|
|
G |
Asprv1 |
aspartic peptidase, retroviral-like 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ASPRV1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 4:119,076,169...119,078,887
Ensembl chr 4:119,077,356...119,078,379
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ATF3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
EXP ISO |
Cacodylic Acid results in increased expression of ATF4 mRNA |
CTD |
PMID:16122865 PMID:23221991 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf7ip2 |
activating transcription factor 7 interacting protein 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ATF7IP2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:5,403,099...5,445,989
Ensembl chr10:5,403,105...5,446,142
|
|
G |
Atp10d |
ATPase phospholipid transporting 10D (putative) |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ATP10D mRNA |
CTD |
PMID:34876320 |
|
NCBI chr14:35,911,728...36,012,549
Ensembl chr14:35,912,141...36,012,564
|
|
G |
Atp6v0a4 |
ATPase H+ transporting V0 subunit a4 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of ATP6V0A4 mRNA |
CTD |
PMID:32052077 |
|
NCBI chr 4:66,760,159...66,842,110
Ensembl chr 4:66,760,159...66,842,110
|
|
G |
Atp7b |
ATPase copper transporting beta |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ATP7B mRNA |
CTD |
PMID:34876320 |
|
NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636
|
|
G |
B3galt5 |
Beta-1,3-galactosyltransferase 5 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of B3GALT5 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr11:35,584,273...35,630,922
Ensembl chr11:35,585,220...35,630,917
|
|
G |
B3gnt5 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of B3GNT5 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr11:81,141,102...81,153,206
Ensembl chr11:81,140,599...81,156,166
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression |
EXP ISO |
Cacodylic Acid results in increased expression of BAD mRNA Cacodylic Acid results in increased expression of BAD mRNA; Cacodylic Acid results in increased expression of BAD protein |
CTD |
PMID:16122865 PMID:22246474 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bank1 |
B-cell scaffold protein with ankyrin repeats 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BANK1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:224,530,475...224,800,420
Ensembl chr 2:224,530,475...224,800,405
|
|
G |
Banp |
Btg3 associated nuclear protein |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of BANP mRNA |
CTD |
PMID:34876320 |
|
NCBI chr19:50,007,710...50,082,742
Ensembl chr19:50,007,881...50,082,738
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
Cacodylic Acid results in increased expression of BAX mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bckdk |
branched chain ketoacid dehydrogenase kinase |
decreases expression |
EXP |
Cacodylic Acid results in decreased expression of BCKDK mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 1:182,515,335...182,520,007
Ensembl chr 1:182,515,327...182,536,633
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
ISO |
Cacodylic Acid results in increased expression of BCL2 mRNA; Cacodylic Acid results in increased expression of BCL2 protein |
CTD |
PMID:22246474 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of BCL2L1 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcorl1 |
BCL6 co-repressor-like 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of BCORL1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr X:127,516,504...127,584,529
Ensembl chr X:127,537,538...127,584,087
|
|
G |
Bex3 |
brain expressed X-linked 3 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of BEX3 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr X:99,273,238...99,274,799
Ensembl chr X:99,273,161...99,274,800
|
|
G |
Bfar |
bifunctional apoptosis regulator |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of BFAR mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:1,552,019...1,585,040
Ensembl chr10:1,552,072...1,585,038
|
|
G |
Bhlhe41 |
basic helix-loop-helix family, member e41 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BHLHE41 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 4:178,833,085...178,838,685
Ensembl chr 4:178,834,271...178,838,468
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases expression multiple interactions |
EXP ISO |
Cacodylic Acid results in increased expression of BIRC5 mRNA; Cacodylic Acid results in increased expression of BIRC5 protein Cacodylic Acid inhibits the reaction [sodium arsenite results in increased expression of BIRC5 protein]; monoisoamyl-2,3-dimercaptosuccinate inhibits the reaction [Cacodylic Acid results in increased expression of BIRC5 mRNA] |
CTD |
PMID:32474354 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Blk |
BLK proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BLK mRNA |
CTD |
PMID:34876320 |
|
NCBI chr15:37,626,746...37,665,053
Ensembl chr15:37,627,039...37,665,031
|
|
G |
Bmp1 |
bone morphogenetic protein 1 |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of BMP1 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr15:45,551,603...45,595,862
Ensembl chr15:45,551,603...45,595,776
|
|
G |
Bmpr1a |
bone morphogenetic protein receptor type 1A |
increases expression |
EXP |
Cacodylic Acid results in increased expression of BMPR1A mRNA |
CTD |
PMID:17720352 |
|
NCBI chr16:9,736,390...9,829,825
Ensembl chr16:9,736,630...9,780,616
|
|
G |
Bok |
BCL2 family apoptosis regulator BOK |
increases expression |
EXP |
Cacodylic Acid results in increased expression of BOK mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 9:94,223,493...94,234,476
Ensembl chr 9:94,223,389...94,234,476
|
|
G |
Bri3bp |
Bri3 binding protein |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BRI3BP mRNA |
CTD |
PMID:34876320 |
|
NCBI chr12:31,176,742...31,188,563
Ensembl chr12:31,173,971...31,188,572
|
|
G |
Btk |
Bruton tyrosine kinase |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BTK mRNA |
CTD |
PMID:34876320 |
|
NCBI chr X:97,722,796...97,762,315
Ensembl chr X:97,722,802...97,761,853
|
|
G |
Btla |
B and T lymphocyte associated |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BTLA mRNA |
CTD |
PMID:34876320 |
|
NCBI chr11:55,563,683...55,588,187
Ensembl chr11:55,564,899...55,587,181
|
|
G |
C1qtnf3 |
C1q and TNF related 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of C1QTNF3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:59,917,099...59,939,519
Ensembl chr 2:59,917,188...59,939,433
|
|
G |
C7 |
complement C7 |
multiple interactions |
ISO |
[Arsenic results in increased abundance of Cacodylic Acid] which affects the expression of C7 mRNA |
CTD |
PMID:28793237 |
|
NCBI chr 2:54,088,116...54,165,102
Ensembl chr 2:54,088,116...54,158,535
|
|
G |
C9 |
complement C9 |
multiple interactions |
ISO |
[Arsenic results in increased abundance of Cacodylic Acid] which affects the expression of C9 mRNA |
CTD |
PMID:28793237 |
|
NCBI chr 2:55,573,094...55,621,345
Ensembl chr 2:55,572,992...55,621,338
|
|
G |
Cacna1i |
calcium voltage-gated channel subunit alpha1 I |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CACNA1I mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:111,835,996...111,947,418
Ensembl chr 7:111,836,012...111,944,688
|
|
G |
Calm2 |
calmodulin 2 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of CALM2 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287
|
|
G |
Calu |
calumenin |
increases expression |
EXP |
Cacodylic Acid results in increased expression of CALU mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593
|
|
G |
Camk1g |
calcium/calmodulin-dependent protein kinase IG |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CAMK1G mRNA |
CTD |
PMID:34876320 |
|
NCBI chr13:104,877,909...104,901,658
Ensembl chr13:104,877,910...104,901,556
|
|
G |
Cap1 |
cyclase associated actin cytoskeleton regulatory protein 1 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of CAP1 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 5:135,142,108...135,168,885
Ensembl chr 5:135,142,112...135,168,769
|
|
G |
Capn3 |
calpain 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CAPN3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 3:107,407,518...107,457,858
Ensembl chr 3:107,407,850...107,457,858
|
|
G |
Capn9 |
calpain 9 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of CAPN9 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr19:52,549,448...52,586,413
Ensembl chr19:52,549,448...52,586,413
|
|
G |
Car12 |
carbonic anhydrase 12 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of CA12 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr 8:67,274,739...67,330,428
Ensembl chr 8:67,274,359...67,330,440
|
|
G |
Car13 |
carbonic anhydrase 13 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of CAR13 mRNA |
CTD |
PMID:17441966 |
|
NCBI chr 2:86,928,401...86,959,525
Ensembl chr 2:86,928,383...86,959,525
|
|
G |
Car3 |
carbonic anhydrase 3 |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of CAR3 mRNA |
CTD |
PMID:17441966 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
Card11 |
caspase recruitment domain family, member 11 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CARD11 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr12:13,620,979...13,758,115
Ensembl chr12:13,621,087...13,758,112
|
|
G |
Carmil2 |
capping protein regulator and myosin 1 linker 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CARMIL2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr19:33,571,255...33,586,783
Ensembl chr19:33,574,257...33,586,965
|
|
G |
Casp12 |
caspase 12 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of CASP12 mRNA; Cacodylic Acid results in increased expression of CASP12 protein |
CTD |
PMID:22246474 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp2 |
caspase 2 |
increases expression |
ISO |
Cacodylic Acid analog results in increased expression of CASP2 protein |
CTD |
PMID:23994116 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases expression increases response to substance |
EXP ISO |
benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [CASP3 protein results in increased susceptibility to Cacodylic Acid]; Buthionine Sulfoximine inhibits the reaction [Cacodylic Acid results in increased activity of CASP3 protein] [sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of CASP3 mRNA Cacodylic Acid analog results in increased activity of CASP3 protein; Cacodylic Acid results in increased activity of CASP3 protein Cacodylic Acid results in increased expression of CASP3 mRNA |
CTD |
PMID:15276415 PMID:16122865 PMID:19465042 PMID:23192986 PMID:23994116 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp6 |
caspase 6 |
affects binding |
ISO |
CASP6 protein binds to Cacodylic Acid analog |
CTD |
PMID:21912678 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases response to substance |
EXP |
benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [CASP8 protein results in increased susceptibility to Cacodylic Acid] |
CTD |
PMID:15276415 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases response to substance |
EXP |
benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [CASP9 protein results in increased susceptibility to Cacodylic Acid] |
CTD |
PMID:15276415 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
increases expression increases activity decreases activity multiple interactions |
EXP |
Cacodylic Acid results in increased expression of CAT mRNA Cacodylic Acid results in increased activity of CAT protein Cacodylic Acid results in decreased activity of CAT protein [CAT protein results in decreased oxidation of dimethylarsinous acid] which results in decreased chemical synthesis of Cacodylic Acid; monoisoamyl-2,3-dimercaptosuccinate inhibits the reaction [Cacodylic Acid results in increased activity of CAT protein] |
CTD |
PMID:16122865 PMID:18619986 PMID:24095718 PMID:32474354 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Catsper4 |
cation channel, sperm associated 4 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CATSPER4 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:146,427,682...146,447,346
Ensembl chr 5:146,427,683...146,446,942
|
|
G |
Cav2 |
caveolin 2 |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of CAV2 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr 4:45,616,766...45,624,144
Ensembl chr 4:45,616,712...45,624,244
|
|
G |
Ccdc122 |
coiled-coil domain containing 122 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC122 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr15:52,407,806...52,470,050
Ensembl chr15:52,407,717...52,470,163
|
|
G |
Ccdc162 |
coiled-coil domain containing 162 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC162 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr20:45,044,891...45,237,905
Ensembl chr20:45,032,752...45,236,193
|
|
G |
Ccdc71l |
coiled-coil domain containing 71-like |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CCDC71L mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 6:48,959,913...48,964,112
Ensembl chr 6:48,960,191...48,960,841
|
|
G |
Ccdc78 |
coiled-coil domain containing 78 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC78 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:14,808,355...14,812,284
Ensembl chr10:14,807,710...14,812,282
|
|
G |
Ccdc87 |
coiled-coil domain containing 87 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC87 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:202,135,021...202,137,717
Ensembl chr 1:202,134,963...202,138,337
|
|
G |
Ccdc92b |
coiled-coil domain containing 92B |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC92B mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:59,479,798...59,501,482
Ensembl chr10:59,479,743...59,501,495
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of CCL11 mRNA |
CTD |
PMID:32052077 |
|
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
|
|
G |
Ccl22 |
C-C motif chemokine ligand 22 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCL22 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400
|
|
G |
Ccl26 |
C-C motif chemokine ligand 26 |
multiple interactions |
ISO |
[Arsenic results in increased abundance of Cacodylic Acid] which affects the expression of CCL26 mRNA |
CTD |
PMID:28793237 |
|
NCBI chr12:21,109,384...21,114,336
Ensembl chr12:21,109,421...21,114,335
|
|
G |
Ccn1 |
cellular communication network factor 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CCN1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccnc |
cyclin C |
increases expression multiple interactions |
ISO |
Cacodylic Acid results in increased expression of CCNC mRNA OGG1 protein inhibits the reaction [Cacodylic Acid results in increased expression of CCNC mRNA] |
CTD |
PMID:17441966 |
|
NCBI chr 5:35,266,828...35,284,943
Ensembl chr 5:35,266,823...35,296,584
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of CCND1 mRNA; Cacodylic Acid results in increased expression of CCND1 protein |
CTD |
PMID:12151359 PMID:17481689 PMID:24832369 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
affects expression |
EXP |
Cacodylic Acid affects the expression of CCND2 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccr6 |
C-C motif chemokine receptor 6 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCR6 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:52,474,477...52,508,301
Ensembl chr 1:52,474,168...52,498,603
|
|
G |
Ccr7 |
C-C motif chemokine receptor 7 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCR7 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309
|
|
G |
Cd180 |
CD180 molecule |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD180 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:33,855,940...33,870,046
Ensembl chr 2:33,855,991...33,899,936
|
|
G |
Cd2 |
Cd2 molecule |
increases expression multiple interactions |
EXP ISO |
Cacodylic Acid results in increased expression of CD2 mRNA [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD2 mRNA |
CTD |
PMID:16122865 PMID:34876320 |
|
NCBI chr 2:188,710,895...188,724,044
Ensembl chr 2:188,710,900...188,724,026
|
|
G |
Cd22 |
CD22 molecule |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD22 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:86,116,376...86,132,782
Ensembl chr 1:86,117,459...86,132,322
|
|
G |
Cd28 |
Cd28 molecule |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD28 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685
|
|
G |
Cd36 |
CD36 molecule |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of CD36 mRNA |
CTD |
PMID:23221991 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd37 |
CD37 molecule |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD37 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:95,719,171...95,724,662
Ensembl chr 1:95,719,190...95,724,648
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD40 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd46 |
CD46 molecule |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD46 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr13:106,575,586...106,606,325
Ensembl chr13:106,574,858...106,660,445
|
|
G |
Cd5 |
Cd5 molecule |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD5 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:207,365,337...207,386,313
Ensembl chr 1:207,365,337...207,386,313
|
|
G |
Cd52 |
CD52 molecule |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD52 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:146,319,789...146,321,348
Ensembl chr 5:146,319,969...146,321,348
|
|
G |
Cd53 |
Cd53 molecule |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD53 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:194,352,139...194,399,668
Ensembl chr 2:194,352,139...194,399,657
|
|
G |
Cd6 |
Cd6 molecule |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD6 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:207,442,873...207,481,703
Ensembl chr 1:207,442,877...207,481,634
|
|
G |
Cd68 |
Cd68 molecule |
increases expression |
ISO |
Cacodylic Acid results in increased expression of CD68 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cd69 |
Cd69 molecule |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD69 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542
|
|
G |
Cd79a |
CD79a molecule |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD79A mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:80,493,520...80,497,936
Ensembl chr 1:80,493,581...80,497,935
|
|
G |
Cd79b |
CD79b molecule |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD79B mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:91,239,354...91,242,500
Ensembl chr10:91,239,356...91,242,625
|
|
G |
Cd83 |
CD83 molecule |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD83 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083
|
|
G |
Cd84 |
CD84 molecule |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD84 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr13:84,327,580...84,367,153
Ensembl chr13:84,327,553...84,362,076
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD86 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdc123 |
cell division cycle 123 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of CDC123 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr17:72,459,296...72,502,948
Ensembl chr17:72,459,282...72,503,316
|
|
G |
Cdc37 |
cell division cycle 37, HSP90 cochaperone |
increases expression |
EXP |
Cacodylic Acid results in increased expression of CDC37 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 8:19,677,400...19,690,761
Ensembl chr 8:19,671,938...19,690,809
|
|
G |
Cdc42ep2 |
CDC42 effector protein 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CDC42EP2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:203,202,000...203,210,891
Ensembl chr 1:203,201,873...203,210,897
|
|
G |
Cdc5l |
cell division cycle 5-like |
increases expression |
EXP |
Cacodylic Acid results in increased expression of CDC5L mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 9:15,564,949...15,603,453
Ensembl chr 9:15,564,767...15,603,450
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of CDH1 mRNA |
CTD |
PMID:16122865 PMID:17481689 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh13 |
cadherin 13 |
affects expression |
EXP |
Cacodylic Acid affects the expression of CDH13 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr19:46,349,562...47,387,462
Ensembl chr19:46,349,430...47,387,459
|
|
G |
Cdh4 |
cadherin 4 |
increases expression multiple interactions |
ISO |
Cacodylic Acid results in increased expression of CDH4 mRNA OGG1 protein inhibits the reaction [Cacodylic Acid results in increased expression of CDH4 mRNA] |
CTD |
PMID:17441966 |
|
NCBI chr 3:166,525,098...167,003,380
Ensembl chr 3:166,525,099...167,003,371
|
|
G |
Cdh8 |
cadherin 8 |
decreases expression |
EXP |
Cacodylic Acid results in decreased expression of CDH8 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr19:5,494,038...5,901,810
Ensembl chr19:5,494,174...5,895,669
|
|
G |
Cdk9 |
cyclin-dependent kinase 9 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of CDK9 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr 3:15,996,467...16,001,315
Ensembl chr 3:15,996,468...16,002,410
|
|
G |
Cdkl1 |
cyclin dependent kinase like 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CDKL1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 6:88,224,154...88,273,434
Ensembl chr 6:88,224,143...88,270,276
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression multiple interactions |
EXP ISO |
Cacodylic Acid results in decreased expression of CDKN1A mRNA; Cacodylic Acid results in decreased expression of CDKN1A protein [sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of CDKN1A mRNA |
CTD |
PMID:12151359 PMID:17481689 PMID:23192986 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
decreases expression decreases methylation |
EXP ISO |
Cacodylic Acid results in decreased expression of CDKN2A mRNA Cacodylic Acid results in decreased methylation of CDKN2A promoter alternative form |
CTD |
PMID:16122865 PMID:23073540 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
decreases expression |
EXP |
Cacodylic Acid results in decreased expression of CDKN2B mRNA |
CTD |
PMID:17720352 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Ceacam6 |
CEA cell adhesion molecule 6 |
multiple interactions |
ISO |
[Arsenic results in increased abundance of Cacodylic Acid] which affects the expression of CEACAM6 mRNA |
CTD |
PMID:28793237 |
|
NCBI chr 1:80,416,531...80,434,668
Ensembl chr 1:80,416,531...80,434,668
|
|
G |
Cebpg |
CCAAT/enhancer binding protein gamma |
decreases expression |
EXP |
Cacodylic Acid results in decreased expression of CEBPG mRNA |
CTD |
PMID:17720352 |
|
NCBI chr 1:87,683,060...87,692,772
Ensembl chr 1:87,684,019...87,694,569
|
|
G |
Cecr2 |
CECR2, histone acetyl-lysine reader |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CECR2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 4:153,890,310...153,998,078
Ensembl chr 4:153,890,206...153,993,451
|
|
G |
Celsr3 |
cadherin, EGF LAG seven-pass G-type receptor 3 |
decreases expression |
EXP |
Cacodylic Acid results in decreased expression of CELSR3 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 8:109,530,597...109,558,360
Ensembl chr 8:109,530,641...109,558,354
|
|
G |
Cemip |
cell migration inducing hyaluronidase 1 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of CEMIP mRNA |
CTD |
PMID:32052077 |
|
NCBI chr 1:137,906,921...138,062,430
Ensembl chr 1:137,908,920...138,062,415
|
|
G |
Cfap47 |
cilia and flagella associated protein 47 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CFAP47 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr X:43,264,687...43,616,607
Ensembl chr X:43,263,490...43,616,852
|
|
G |
Cfd |
complement factor D |
increases expression multiple interactions |
ISO |
Cacodylic Acid results in increased expression of CFD mRNA OGG1 protein inhibits the reaction [Cacodylic Acid results in increased expression of CFD mRNA] |
CTD |
PMID:17441966 |
|
NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
|
|
G |
Chad |
chondroadherin |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CHAD mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:79,512,170...79,515,941
Ensembl chr10:79,511,931...79,515,940
|
|
G |
Chat |
choline O-acetyltransferase |
increases activity |
ISO |
Cacodylic Acid results in increased activity of CHAT protein |
CTD |
PMID:21440049 |
|
NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
|
|
G |
Chek2 |
checkpoint kinase 2 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of CHEK2 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of CHIL1 mRNA |
CTD |
PMID:32052077 |
|
NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787
|
|
G |
Chordc1 |
cysteine and histidine rich domain containing 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CHORDC1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:15,374,356...15,398,436
Ensembl chr 8:15,374,471...15,399,162
|
|
G |
Chrna9 |
cholinergic receptor nicotinic alpha 9 subunit |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CHRNA9 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr14:42,235,218...42,241,939
Ensembl chr14:42,235,226...42,242,192
|
|
G |
Chst3 |
carbohydrate sulfotransferase 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CHST3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr20:28,114,387...28,152,046
Ensembl chr20:28,114,404...28,121,807
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
increases expression |
EXP |
Cacodylic Acid results in increased expression of CHUK mRNA; Cacodylic Acid results in increased expression of CHUK protein |
CTD |
PMID:26617437 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Ciart |
circadian associated repressor of transcription |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CIART mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:183,419,819...183,424,845
Ensembl chr 2:183,419,819...183,423,313
|
|
G |
Ciita |
class II, major histocompatibility complex, transactivator |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CIITA mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:5,139,947...5,187,493
Ensembl chr10:5,140,178...5,187,440
|
|
G |
Cilp |
cartilage intermediate layer protein |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CILP mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:65,777,281...65,792,251
Ensembl chr 8:65,777,281...65,792,251
|
|
G |
Cirbp |
cold inducible RNA binding protein |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CIRBP mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:9,533,857...9,538,899
Ensembl chr 7:9,424,178...9,538,818
|
|
G |
Clca4 |
chloride channel accessory 4 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CLCA4B mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:233,883,625...233,904,993
Ensembl chr 2:233,883,851...233,903,089
|
|
G |
Clcf1 |
cardiotrophin-like cytokine factor 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CLCF1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:201,507,763...201,517,607
Ensembl chr 1:201,507,859...201,517,605
|
|
G |
Clec2dl1 |
C-type lectin domain family 2 member D-like 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CLEC2I mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 4:162,263,578...162,274,882
Ensembl chr 4:162,263,639...162,274,880
|
|
G |
Clec7a |
C-type lectin domain containing 7A |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CLEC7A mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 4:162,902,731...162,913,931
Ensembl chr 4:162,902,732...162,913,897
|
|
G |
Clu |
clusterin |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CLU mRNA |
CTD |
PMID:34876320 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CNR2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Coch |
cochlin |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of COCH mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 6:69,031,139...69,045,124
Ensembl chr 6:69,031,167...69,045,109
|
|
G |
Col11a2 |
collagen type XI alpha 2 chain |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of COL11A2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr20:4,786,929...4,816,598
Ensembl chr20:4,786,929...4,815,985
|
|
G |
Col7a1 |
collagen type VII alpha 1 chain |
decreases expression multiple interactions |
ISO |
Cacodylic Acid results in decreased expression of COL7A1 mRNA [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of COL7A1 mRNA |
CTD |
PMID:17441966 PMID:34876320 |
|
NCBI chr 8:109,604,877...109,637,252
Ensembl chr 8:109,604,861...109,637,252
|
|
G |
Colq |
collagen like tail subunit of asymmetric acetylcholinesterase |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of COLQ mRNA |
CTD |
PMID:34876320 |
|
NCBI chr16:6,731,850...6,824,973
Ensembl chr16:6,731,858...6,787,107
|
|
G |
Comp |
cartilage oligomeric matrix protein |
increases expression |
EXP |
Cacodylic Acid results in increased expression of COMP mRNA |
CTD |
PMID:16122865 |
|
NCBI chr16:19,047,206...19,055,584
Ensembl chr16:19,047,207...19,055,845
|
|
G |
Coro1a |
coronin 1A |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CORO1A mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:181,295,561...181,300,566
Ensembl chr 1:181,295,562...181,300,534
|
|
G |
Cotl1 |
coactosin-like F-actin binding protein 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of COTL1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr19:47,871,689...47,906,010
Ensembl chr19:47,871,694...47,911,689
|
|
G |
Cpd |
carboxypeptidase D |
decreases expression |
EXP |
Cacodylic Acid results in decreased expression of CPD mRNA |
CTD |
PMID:17720352 |
|
NCBI chr10:61,623,528...61,687,491
Ensembl chr10:61,623,526...61,687,491
|
|
G |
Cpsf4l |
cleavage and polyadenylation specific factor 4-like |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CPSF4L mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:98,741,816...98,756,069
Ensembl chr10:98,743,649...98,751,590
|
|
G |
Cpxm1 |
carboxypeptidase X (M14 family), member 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CPXM1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 3:117,588,532...117,595,330
Ensembl chr 3:117,588,532...117,595,330
|
|
G |
Cr2 |
complement C3d receptor 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CR2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr13:106,678,579...106,716,595
Ensembl chr13:106,685,413...106,716,235
|
|
G |
Crppa |
CDP-L-ribitol pyrophosphorylase A |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CRPPA mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 6:53,120,264...53,397,030
Ensembl chr 6:53,121,438...53,397,028
|
|
G |
Crtam |
cytotoxic and regulatory T cell molecule |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CRTAM mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:41,340,117...41,377,343
Ensembl chr 8:41,340,837...41,377,343
|
|
G |
Cry1 |
cryptochrome circadian regulator 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CRY1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091
|
|
G |
Csrnp2 |
cysteine and serine rich nuclear protein 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CSRNP2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:131,594,232...131,610,075
Ensembl chr 7:131,594,232...131,610,075
|
|
G |
Ctnna3 |
catenin alpha 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CTNNA3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr20:23,614,469...25,200,026
Ensembl chr20:23,623,560...25,199,978
|
|
G |
Ctnnd2 |
catenin delta 2 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of CTNND2 mRNA |
CTD |
PMID:17441966 |
|
NCBI chr 2:81,168,976...82,016,495
Ensembl chr 2:81,167,117...82,015,764
|
|
G |
Ctsg |
cathepsin G |
multiple interactions |
ISO |
[Arsenic results in increased abundance of Cacodylic Acid] which affects the expression of CTSG mRNA |
CTD |
PMID:28793237 |
|
NCBI chr15:29,930,988...29,937,353
Ensembl chr15:29,931,003...29,937,353
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CXCL10 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl17 |
C-X-C motif chemokine ligand 17 |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of CXCL17 mRNA |
CTD |
PMID:32052077 |
|
NCBI chr 1:80,984,751...80,996,842
Ensembl chr 1:80,984,964...80,996,726
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CXCL9 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CYBB mRNA |
CTD |
PMID:34876320 |
|
NCBI chr X:13,360,583...13,392,517
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
AHR mutant form inhibits the reaction [Cacodylic Acid results in increased expression of CYP1A1 protein]; Cacodylic Acid promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of and results in increased activity of CYP1A1 protein]; Cacodylic Acid promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Cacodylic Acid results in increased expression of and results in increased activity of CYP1A1 protein [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CYP1A1 mRNA; Cacodylic Acid affects the reaction [[Tetrachlorodibenzodioxin results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA]; Cacodylic Acid affects the reaction [[Tetrachlorodibenzodioxin results in increased activity of AHR protein] which results in increased expression of CYP1A1 protein] Cacodylic Acid results in increased expression of CYP1A1 mRNA |
CTD |
PMID:24161444 PMID:28134025 PMID:34876320 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of CYP1A2 mRNA |
CTD |
PMID:17481689 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions increases expression |
EXP |
[Cacodylic Acid co-treated with Diethylnitrosamine] results in increased expression of CYP2B1 mRNA; [Cacodylic Acid co-treated with Diethylnitrosamine] results in increased expression of CYP2B1 protein Cacodylic Acid results in increased expression of CYP2B1 mRNA |
CTD |
PMID:12115560 PMID:17481689 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
multiple interactions |
EXP |
[Cacodylic Acid co-treated with Diethylnitrosamine] results in increased expression of CYP2B2 mRNA |
CTD |
PMID:12115560 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:17481689 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CYP4F18 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
increases expression multiple interactions |
ISO |
Cacodylic Acid results in increased expression of CYP7B1 mRNA OGG1 protein inhibits the reaction [Cacodylic Acid results in increased expression of CYP7B1 mRNA] |
CTD |
PMID:17441966 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Dab1 |
DAB adaptor protein 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DAB1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:118,392,953...119,513,625
Ensembl chr 5:119,140,533...119,510,552
|
|
G |
Dbp |
D-box binding PAR bZIP transcription factor |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DBP mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:96,175,796...96,180,745
Ensembl chr 1:96,175,440...96,180,745
|
|
G |
Dclk3 |
doublecortin-like kinase 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DCLK3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:111,401,544...111,453,999
Ensembl chr 8:111,401,358...111,453,999
|
|
G |
Ddb2 |
damage specific DNA binding protein 2 |
multiple interactions |
ISO |
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of DDB2 mRNA |
CTD |
PMID:23192986 |
|
NCBI chr 3:77,185,114...77,207,650
Ensembl chr 3:77,185,109...77,207,631
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of DDIT3 mRNA |
CTD |
PMID:23221991 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddx3y |
DEAD-box helicase 3, Y-linked |
increases expression |
ISO |
Cacodylic Acid results in increased expression of DDX3Y mRNA |
CTD |
PMID:22246474 |
|
NCBI chr13:98,520,538...98,523,707
Ensembl chr13:98,520,201...98,524,176
|
|
G |
Def6 |
DEF6 guanine nucleotide exchange factor |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DEF6 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr20:6,268,614...6,290,030
Ensembl chr20:6,268,601...6,289,961
|
|
G |
Dgkb |
diacylglycerol kinase, beta |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of DGKB mRNA |
CTD |
PMID:32052077 |
|
NCBI chr 6:54,640,948...55,397,210
Ensembl chr 6:54,641,614...55,397,043
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DHCR7 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dhrs9 |
dehydrogenase/reductase 9 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DHRS9 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 3:54,147,834...54,170,052
Ensembl chr 3:54,147,803...54,220,241
|
|
G |
Diras2 |
DIRAS family GTPase 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DIRAS2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr17:12,730,040...12,761,511
Ensembl chr17:12,725,149...12,761,663
|
|
G |
Dnah10 |
dynein, axonemal, heavy chain 10 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DNAH10 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr12:31,823,451...31,946,857
Ensembl chr12:31,822,733...32,007,069
|
|
G |
Dnai4 |
dynein axonemal intermediate chain 4 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DNAI4 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:117,787,398...117,876,140
Ensembl chr 5:117,788,464...117,876,127
|
|
G |
Dnajb13 |
DnaJ heat shock protein family (Hsp40) member B13 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DNAJB13 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:154,848,586...154,863,042
Ensembl chr 1:154,848,594...154,862,963
|
|
G |
Dnajb3 |
DnaJ heat shock protein family (Hsp40) member B3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DNAJB3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 9:88,795,542...88,796,555
Ensembl chr 9:88,795,488...88,796,560
|
|
G |
Dnase1l2 |
deoxyribonuclease 1 like 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DNASE1L2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:13,471,850...13,473,447
Ensembl chr10:13,471,479...13,473,763
|
|
G |
Dnase1l3 |
deoxyribonuclease 1-like 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DNASE1L3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr15:16,922,335...16,948,322
Ensembl chr15:16,922,335...16,948,317
|
|
G |
Dock10 |
dedicator of cytokinesis 10 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DOCK10 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 9:81,843,599...82,101,540
Ensembl chr 9:81,843,604...82,101,525
|
|
G |
Dock2 |
dedicator of cytokinesis 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DOCK2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:18,827,237...19,244,823
Ensembl chr10:18,827,239...19,244,808
|
|
G |
Dok3 |
docking protein 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DOK3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr17:9,109,633...9,115,188
Ensembl chr17:9,109,597...9,115,188
|
|
G |
Drd3 |
dopamine receptor D3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DRD3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596
|
|
G |
Duox2 |
dual oxidase 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DUOX2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 3:109,223,809...109,247,023
Ensembl chr 3:109,226,924...109,245,902
|
|
G |
Duoxa1 |
dual oxidase maturation factor 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DUOXA1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 3:109,249,815...109,260,511
Ensembl chr 3:109,249,923...109,260,499
|
|
G |
Duoxa2 |
dual oxidase maturation factor 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DUOXA2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 3:109,245,476...109,248,844
Ensembl chr 3:109,245,476...109,248,968
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DUSP1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:16,680,489...16,683,276
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DUSP2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 3:114,556,325...114,558,510
Ensembl chr 3:114,556,325...114,558,499
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DUSP6 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185
|
|
G |
Eaf2 |
ELL associated factor 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of EAF2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr11:63,960,200...64,004,610
Ensembl chr11:63,960,200...64,004,610
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of EDN1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
decreases expression |
EXP |
Cacodylic Acid results in decreased expression of EEF1A1 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839
|
|
G |
Efna3 |
ephrin A3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of EFNA3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:174,729,192...174,738,111
Ensembl chr 2:174,729,764...174,738,736
|
|
G |
Egfr |
epidermal growth factor receptor |
increases expression |
EXP |
Cacodylic Acid results in increased expression of EGFR mRNA |
CTD |
PMID:16122865 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
increases expression multiple interactions |
ISO |
Cacodylic Acid results in increased expression of EGR1 mRNA [Arsenic results in increased abundance of Cacodylic Acid] which affects the expression of EGR1 mRNA; [sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of EGR1 mRNA |
CTD |
PMID:15345372 PMID:23192986 PMID:28793237 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr3 |
early growth response 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of EGR3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr15:45,150,335...45,156,052
Ensembl chr15:45,150,567...45,154,627
|
|
G |
Ehd3 |
EH-domain containing 3 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of EHD3 mRNA |
CTD |
PMID:32052077 |
|
NCBI chr 6:21,640,861...21,665,601
Ensembl chr 6:21,639,290...21,665,236
|
|
G |
Ehmt2 |
euchromatic histone lysine methyltransferase 2 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of EHMT2 mRNA |
CTD |
PMID:32052077 |
|
NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547
|
|
G |
Elfn2 |
extracellular leucine-rich repeat and fibronectin type III domain containing 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ELFN2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:110,220,293...110,272,770
Ensembl chr 7:110,225,919...110,272,433
|
|
G |
Emb |
embigin |
increases expression |
EXP |
Cacodylic Acid results in increased expression of EMB mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 2:49,070,509...49,125,042
Ensembl chr 2:49,069,087...49,125,050
|
|
G |
Endou |
endonuclease, poly(U)-specific |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ENDOU mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:128,845,862...128,866,542
Ensembl chr 7:128,844,862...128,866,596
|
|
G |
Eomes |
eomesodermin |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of EOMES mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:118,181,340...118,189,186
Ensembl chr 8:118,181,777...118,188,316
|
|
G |
Epm2a |
EPM2A glucan phosphatase, laforin |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of EPM2A mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:5,727,111...5,845,338
Ensembl chr 1:5,727,066...5,920,555
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
EXP |
Cacodylic Acid results in increased expression of and results in increased phosphorylation of ERBB2 protein |
CTD |
PMID:32890875 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Ereg |
epiregulin |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of EREG mRNA |
CTD |
PMID:34876320 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Ervfrd-1 |
endogenous retrovirus group FRD member 1, envelope |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SYNA mRNA |
CTD |
PMID:34876320 |
|
NCBI chr12:22,151,211...22,158,264
Ensembl chr12:22,151,211...22,158,264
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of ESR1 mRNA |
CTD |
PMID:23192986 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Etnk2 |
ethanolamine kinase 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ETNK2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr13:44,811,224...44,829,037
Ensembl chr13:44,811,015...44,829,037
|
|
G |
Ets1 |
ETS proto-oncogene 1, transcription factor |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ETS1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010
|
|
G |
Exph5 |
exophilin 5 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of EXPH5 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:53,698,825...53,775,371
Ensembl chr 8:53,698,852...53,773,169
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FABP1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FABP3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
|
|
G |
Fam151a |
family with sequence similarity 151, member A |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FAM151A mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:121,514,804...121,527,555
Ensembl chr 5:121,514,804...121,527,555
|
|
G |
Fam161b |
FAM161 centrosomal protein B |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FAM161B mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 6:103,990,603...104,007,754
Ensembl chr 6:103,992,170...104,018,776
|
|
G |
Fam169b |
family with sequence similarity 169, member B |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FAM169B mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:121,878,670...121,968,272
Ensembl chr 1:121,878,713...121,958,470
|
|
G |
Fam89a |
family with sequence similarity 89, member A |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FAM89A mRNA |
CTD |
PMID:34876320 |
|
NCBI chr19:52,710,003...52,722,591
Ensembl chr19:52,710,019...52,722,631
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of FAS mRNA |
CTD |
PMID:29864498 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
increases expression decreases expression |
EXP ISO |
Cacodylic Acid results in increased expression of FASLG mRNA Cacodylic Acid results in decreased expression of FASL mRNA |
CTD |
PMID:15345372 PMID:17481689 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fbp1 |
fructose-bisphosphatase 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FBP1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr17:2,207,271...2,230,076
Ensembl chr17:2,208,031...2,230,071
|
|
G |
Fbxl22 |
F-box and leucine-rich repeat protein 22 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FBXL22 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:67,069,998...67,076,685
Ensembl chr 8:67,069,998...67,076,685
|
|
G |
Fbxo24 |
F-box protein 24 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FBXO24 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr12:19,072,668...19,083,067
Ensembl chr12:19,072,716...19,083,067
|
|
G |
Fcer2 |
Fc epsilon receptor II |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FCER2A mRNA |
CTD |
PMID:34876320 |
|
NCBI chr12:1,742,809...1,754,476
Ensembl chr12:1,742,815...1,754,476
|
|
G |
Fcrl1 |
Fc receptor-like 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FCRL1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:172,809,451...172,829,780
Ensembl chr 2:172,790,934...172,829,753
|
|
G |
Fcrla |
Fc receptor-like A |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FCRLA mRNA |
CTD |
PMID:34876320 |
|
NCBI chr13:83,160,453...83,170,170
Ensembl chr13:83,160,398...83,170,762
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FDFT1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fdps |
farnesyl diphosphate synthase |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FDPS mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Fer1l5 |
fer-1-like family member 5 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FER1L5 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 9:38,605,835...38,661,869
Ensembl chr 9:38,607,843...38,660,425
|
|
G |
Fev |
FEV transcription factor, ETS family member |
decreases expression |
EXP |
Cacodylic Acid results in decreased expression of FEV mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 9:76,439,164...76,443,603
Ensembl chr 9:76,439,172...76,443,065
|
|
G |
Ffar1 |
free fatty acid receptor 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FFAR1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:86,111,368...86,112,272
Ensembl chr 1:86,111,368...86,112,272
|
|
G |
Fgf11 |
fibroblast growth factor 11 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FGF11 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:54,516,508...54,522,067
Ensembl chr10:54,517,077...54,522,062
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of FGF2 mRNA |
CTD |
PMID:15345372 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf23 |
fibroblast growth factor 23 |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of FGF23 mRNA |
CTD |
PMID:17441966 |
|
NCBI chr 4:159,914,393...159,922,073
Ensembl chr 4:159,914,272...159,923,821
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of FGF9 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309
|
|
G |
Fgfbp3 |
fibroblast growth factor binding protein 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FGFBP3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:234,644,023...234,646,028
Ensembl chr 1:234,644,019...234,646,547
|
|
G |
Fgr |
FGR proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FGR mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:145,189,814...145,219,571
Ensembl chr 5:145,189,841...145,217,326
|
|
G |
Fibcd1 |
fibrinogen C domain containing 1 |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of FIBCD1 mRNA |
CTD |
PMID:22246474 |
|
NCBI chr 3:15,092,681...15,126,399
Ensembl chr 3:15,092,681...15,126,399
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
multiple interactions |
ISO |
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of FKBP5 mRNA |
CTD |
PMID:23192986 |
|
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Flacc1 |
flagellum associated containing coiled-coil domains 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FLACC1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 9:60,315,581...60,343,692
Ensembl chr 9:60,315,582...60,343,648
|
|
G |
Flg |
filaggrin |
increases expression |
ISO |
Cacodylic Acid results in increased expression of FLG mRNA |
CTD |
PMID:32052077 |
|
NCBI chr 2:178,888,688...178,912,731
|
|
G |
Fli1 |
Fli-1 proto-oncogene, ETS transcription factor |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FLI1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:30,831,422...30,950,468
Ensembl chr 8:30,832,753...30,950,433
|
|
G |
Flnc |
filamin C |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FLNC mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844
|
|
G |
Flt3 |
Fms related receptor tyrosine kinase 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FLT3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr12:7,623,658...7,699,474
Ensembl chr12:7,623,930...7,699,474
|
|
G |
Fndc10 |
fibronectin type III domain containing 10 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FNDC10 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:166,299,587...166,311,477
Ensembl chr 5:166,300,122...166,310,326
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of FOS mRNA [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FOS mRNA |
CTD |
PMID:23192986 PMID:34876320 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxq1 |
forkhead box Q1 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of FOXQ1 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr17:32,912,744...32,915,377
Ensembl chr17:32,912,744...32,915,377 Ensembl chr17:32,912,744...32,915,377
|
|
G |
Fpr1 |
formyl peptide receptor 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FPR1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:58,745,019...58,756,776
Ensembl chr 1:58,747,246...58,756,559
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FSCN1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr12:11,597,042...11,610,183
Ensembl chr12:11,597,048...11,610,211
|
|
G |
Fth1 |
ferritin heavy chain 1 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of FTH1 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Ftl1 |
ferritin light chain 1 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of FTL1 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 1:95,936,390...95,938,234
Ensembl chr 1:95,936,387...95,939,725
|
|
G |
Fut1 |
fucosyltransferase 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FUT1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:96,086,934...96,090,352
Ensembl chr 1:96,086,635...96,090,616
|
|
G |
Fut11 |
fucosyltransferase 11 |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of FUT11 mRNA |
CTD |
PMID:22246474 |
|
NCBI chr15:3,598,768...3,602,328
Ensembl chr15:3,598,758...3,602,356
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression multiple interactions |
EXP ISO |
Cacodylic Acid results in increased expression of GADD45A mRNA [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GADD45A mRNA Cacodylic Acid analog results in increased expression of GADD45A protein |
CTD |
PMID:16122865 PMID:23994116 PMID:34876320 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gak |
cyclin G associated kinase |
increases expression |
EXP |
Cacodylic Acid results in increased expression of GAK mRNA |
CTD |
PMID:16122865 |
|
NCBI chr14:1,089,853...1,164,098
Ensembl chr14:1,089,866...1,216,398
|
|
G |
Gbp4 |
guanylate binding protein 4 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GBP4 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:231,304,910...231,318,883
Ensembl chr 2:231,305,244...231,318,879
|
|
G |
Gbp6 |
guanylate binding protein family member 6 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GBP9 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr14:4,730,286...4,756,508
Ensembl chr14:4,730,453...4,839,062
|
|
G |
Gch1 |
GTP cyclohydrolase 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GCH1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
[Cacodylic Acid results in increased abundance of Arsenic] which results in increased expression of GCLC protein |
CTD |
PMID:33434570 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
[Cacodylic Acid results in increased abundance of Arsenic] which results in increased expression of GCLM protein |
CTD |
PMID:33434570 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gcsam |
germinal center-associated, signaling and motility |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GCSAM mRNA |
CTD |
PMID:34876320 |
|
NCBI chr11:55,195,757...55,207,011
Ensembl chr11:55,196,712...55,206,992
|
|
G |
Gdf15 |
growth differentiation factor 15 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GDF15 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr16:18,805,312...18,807,893
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gdi2 |
GDP dissociation inhibitor 2 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of GDI2 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr17:66,649,616...66,676,299
Ensembl chr17:66,649,619...66,676,366
|
|
G |
Gimap5 |
GTPase, IMAP family member 5 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GIMAP5 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 4:77,693,417...77,701,025
Ensembl chr 4:77,687,564...77,703,086
|
|
G |
Gimap6 |
GTPase, IMAP family member 6 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GIMAP6 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 4:77,653,703...77,659,112
Ensembl chr 4:77,652,610...77,659,116
|
|
G |
Gimap8 |
GTPase, IMAP family member 8 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GIMAP8 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 4:77,600,104...77,611,593
Ensembl chr 4:77,600,186...77,611,590
|
|
G |
Gjb1 |
gap junction protein, beta 1 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of GJB1 mRNA |
CTD |
PMID:17481689 |
|
NCBI chr X:66,501,848...66,509,783
Ensembl chr X:66,501,820...66,509,925
|
|
G |
Gjb4 |
gap junction protein, beta 4 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of GJB4 mRNA |
CTD |
PMID:32052077 |
|
NCBI chr 5:139,675,776...139,679,551
Ensembl chr 5:139,675,780...139,679,667
|
|
G |
Gli1 |
GLI family zinc finger 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GLI1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251
|
|
G |
Glrb |
glycine receptor, beta |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GLRB mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:166,134,624...166,207,509
Ensembl chr 2:166,134,626...166,207,489
|
|
G |
Glrx |
glutaredoxin |
increases expression |
EXP |
Cacodylic Acid results in increased expression of GLRX mRNA |
CTD |
PMID:17720352 |
|
NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680
|
|
G |
Gls2 |
glutaminase 2 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of GLS2 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr 7:617,252...633,424
Ensembl chr 7:617,288...633,426
|
|
G |
Gna15 |
G protein subunit alpha 15 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GNA15 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:8,184,632...8,205,508
Ensembl chr 7:8,184,861...8,205,508
|
|
G |
Gnat1 |
G protein subunit alpha transducin 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GNAT1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:108,350,935...108,355,671
Ensembl chr 8:108,350,935...108,355,671
|
|
G |
Gng5 |
G protein subunit gamma 5 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of GNG5 mRNA |
CTD |
PMID:17441966 |
|
NCBI chr 2:235,394,680...235,403,177
|
|
G |
Gp1bb |
glycoprotein Ib platelet subunit beta |
multiple interactions |
ISO |
[Arsenic results in increased abundance of Cacodylic Acid] which affects the expression of GP1BB mRNA |
CTD |
PMID:28793237 |
|
NCBI chr11:82,378,216...82,379,393
Ensembl chr11:82,378,199...82,379,392
|
|
G |
Gpr132 |
G protein-coupled receptor 132 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR132 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 6:131,924,061...131,943,327
Ensembl chr 6:131,924,160...131,942,168
|
|
G |
Gpr157 |
G protein-coupled receptor 157 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR157 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:160,550,703...160,566,432
Ensembl chr 5:160,550,713...160,566,432
|
|
G |
Gpr17 |
G protein-coupled receptor 17 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GPR17 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr18:23,576,212...23,583,177
Ensembl chr18:23,577,242...23,582,966
|
|
G |
Gpr174 |
G protein-coupled receptor 174 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR174 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr X:72,355,452...72,396,146
Ensembl chr X:72,355,033...72,397,658
|
|
G |
Gpr179 |
G protein-coupled receptor 179 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR179 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:82,324,568...82,340,448
Ensembl chr10:82,337,771...82,340,448
|
|
G |
Gpr18 |
G protein-coupled receptor 18 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR18 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr15:98,997,427...99,001,177
Ensembl chr15:98,997,259...99,001,470
|
|
G |
Gpr183 |
G protein-coupled receptor 183 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR183 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr15:99,037,764...99,050,550
Ensembl chr15:99,036,367...99,050,559
|
|
G |
Gpr34 |
G protein-coupled receptor 34 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR34 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr X:9,104,829...9,113,796
Ensembl chr X:9,104,565...9,148,601
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of GPX1 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx7 |
glutathione peroxidase 7 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GPX7 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:123,145,151...123,153,141
Ensembl chr 5:123,144,331...123,153,004
|
|
G |
Gramd2a |
GRAM domain containing 2A |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GRAMD2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:60,079,744...60,117,788
Ensembl chr 8:60,080,338...60,115,842
|
|
G |
Grap |
GRB2-related adaptor protein |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GRAP mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:46,298,965...46,352,057
Ensembl chr10:46,332,909...46,352,056
|
|
G |
Grn |
granulin precursor |
increases expression |
EXP |
Cacodylic Acid results in increased expression of GRN mRNA |
CTD |
PMID:16122865 |
|
NCBI chr10:87,387,672...87,393,777
Ensembl chr10:87,387,638...87,393,775
|
|
G |
Grpel1 |
GrpE-like 1, mitochondrial |
increases expression |
EXP |
Cacodylic Acid results in increased expression of GRPEL1 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr14:74,292,023...74,298,243
Ensembl chr14:74,292,023...74,298,200
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[Cacodylic Acid results in increased abundance of Arsenic] which results in increased expression of GSR protein |
CTD |
PMID:33434570 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
decreases expression increases expression |
EXP |
Cacodylic Acid results in decreased expression of GSTA2 mRNA; Cacodylic Acid results in decreased expression of GSTA2 protein Cacodylic Acid results in increased expression of GSTA2 mRNA |
CTD |
PMID:16436460 PMID:17481689 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of GSTA4 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
increases expression multiple interactions |
EXP ISO |
Cacodylic Acid results in increased expression of GSTM1 mRNA; Cacodylic Acid results in increased expression of GSTM1 protein [GSTM1 gene polymorphism affects the metabolism of Arsenic] which affects the abundance of Cacodylic Acid |
CTD |
PMID:16436460 PMID:32650499 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of GSTM5 mRNA |
CTD |
PMID:15345372 |
|
NCBI chr 2:195,531,627...195,534,562
Ensembl chr 2:195,531,495...195,534,553
|
|
G |
Gsto2 |
glutathione S-transferase omega 2 |
multiple interactions |
ISO |
[GSTO2 gene polymorphism affects the metabolism of Arsenic] which affects the abundance of Cacodylic Acid |
CTD |
PMID:32650499 |
|
NCBI chr 1:246,731,314...246,757,592
Ensembl chr 1:246,732,089...246,753,866
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases expression decreases expression |
EXP ISO |
Cacodylic Acid results in increased expression of GSTP1 mRNA Cacodylic Acid results in decreased expression of GSTP1 mRNA |
CTD |
PMID:16122865 PMID:17481689 PMID:32052077 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
affects metabolic processing multiple interactions affects response to substance |
ISO |
GSTT1 protein affects the metabolism of Cacodylic Acid [GSTT1 gene polymorphism affects the metabolism of Arsenic] which affects the abundance of Cacodylic Acid GSTT1 gene affects the susceptibility to Cacodylic Acid |
CTD |
PMID:17431481 PMID:32650499 |
|
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
|
|
G |
Gtf2f2 |
general transcription factor IIF subunit 2 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of GTF2F2 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr15:51,206,027...51,327,166
Ensembl chr15:51,206,031...51,327,253
|
|
G |
Guca1b |
guanylate cyclase activator 1B |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GUCA1B mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 9:13,599,619...13,607,455
Ensembl chr 9:13,599,619...13,607,455
|
|
G |
Gzmk |
granzyme K |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GZMK mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:44,840,811...44,848,829
Ensembl chr 2:44,840,811...44,848,894
|
|
G |
H1f0 |
H1.0 linker histone |
increases expression |
EXP |
Cacodylic Acid results in increased expression of H1F0 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 7:110,592,834...110,594,694
Ensembl chr 7:110,592,208...110,594,694
|
|
G |
Haao |
3-hydroxyanthranilate 3,4-dioxygenase |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HAAO mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 6:10,845,235...10,864,863
Ensembl chr 6:10,845,771...10,864,877
|
|
G |
Hapln2 |
hyaluronan and proteoglycan link protein 2 |
decreases expression |
EXP |
Cacodylic Acid results in decreased expression of HAPLN2 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 2:173,488,909...173,496,824
Ensembl chr 2:173,491,160...173,496,588
|
|
G |
Hcls1 |
hematopoietic cell specific Lyn substrate 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HCLS1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr11:63,817,482...63,840,943
Ensembl chr11:63,817,476...63,841,014
|
|
G |
Hcn2 |
hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HCN2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:9,969,801...9,988,839
Ensembl chr 7:9,970,368...9,988,841
|
|
G |
Hdc |
histidine decarboxylase |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HDC mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 3:113,847,256...113,865,334
Ensembl chr 3:113,847,260...113,865,341
|
|
G |
Hhat |
hedgehog acyltransferase |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HHAT mRNA |
CTD |
PMID:34876320 |
|
NCBI chr13:104,024,507...104,283,581
Ensembl chr13:104,010,916...104,282,893
|
|
G |
Hhex |
hematopoietically expressed homeobox |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HHEX mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:235,190,455...235,196,042
Ensembl chr 1:235,190,455...235,196,042
|
|
G |
Higd2a |
HIG1 hypoxia inducible domain family, member 2A |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of HIGD2A mRNA |
CTD |
PMID:32052077 |
|
NCBI chr17:10,021,853...10,022,777
Ensembl chr17:10,021,859...10,022,796
|
|
G |
Hk2 |
hexokinase 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HK2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HMGCS1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HMGCS2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO |
Cacodylic Acid results in increased expression of HMOX1 mRNA [sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of HMOX1 mRNA |
CTD |
PMID:15345372 PMID:23192986 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hoga1 |
4-hydroxy-2-oxoglutarate aldolase 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HOGA1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:240,856,991...240,884,243
Ensembl chr 1:240,857,126...240,884,568
|
|
G |
Hoxa1 |
homeobox A1 |
decreases expression |
EXP |
Cacodylic Acid results in decreased expression of HOXA1 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 4:81,255,814...81,258,504
Ensembl chr 4:81,255,883...81,258,504
|
|
G |
Hoxa2 |
homeobox A2 |
decreases expression |
EXP |
Cacodylic Acid results in decreased expression of HOXA2 mRNA |
CTD |
PMID:16122865 |
|
Ensembl chr 4:81,262,768...81,265,044
|
|
G |
Hpca |
hippocalcin |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HPCA mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:141,455,616...141,466,252
Ensembl chr 5:141,455,613...141,463,841
|
|
G |
Hs3st3b1 |
heparan sulfate-glucosamine 3-sulfotransferase 3B1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HS3ST3B1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:48,561,473...48,593,970
Ensembl chr10:48,561,473...48,593,970
|
|
G |
Hsf2bp |
heat shock transcription factor 2 binding protein |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HSF2BP mRNA |
CTD |
PMID:34876320 |
|
NCBI chr20:10,035,562...10,123,059
Ensembl chr20:10,035,562...10,121,242
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HSPA1A mRNA |
CTD |
PMID:34876320 |
|
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
multiple interactions decreases expression |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HSPA1B mRNA; OGG1 protein inhibits the reaction [Cacodylic Acid results in decreased expression of HSPA1B mRNA] |
CTD |
PMID:17441966 PMID:34876320 |
|
NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240
|
|
G |
Hspa4l |
heat shock protein family A (Hsp70) member 4 like |
multiple interactions decreases expression |
ISO |
OGG1 protein inhibits the reaction [Cacodylic Acid results in decreased expression of HSPA4L mRNA] |
CTD |
PMID:17441966 |
|
NCBI chr 2:123,740,384...123,793,088
Ensembl chr 2:123,740,384...123,793,084
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of HSPA5 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
decreases expression multiple interactions |
ISO |
Cacodylic Acid results in decreased expression of HSPA8 mRNA [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HSPA8 mRNA; OGG1 protein inhibits the reaction [Cacodylic Acid results in decreased expression of HSPA8 mRNA] |
CTD |
PMID:17441966 PMID:34876320 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
decreases expression multiple interactions |
ISO |
Cacodylic Acid results in decreased expression of HSPB1 mRNA OGG1 protein inhibits the reaction [Cacodylic Acid results in decreased expression of HSPB1 mRNA] |
CTD |
PMID:17441966 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Hspb7 |
heat shock protein family B (small) member 7 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HSPB7 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:153,727,782...153,731,268
Ensembl chr 5:153,727,588...153,731,266
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of HSPD1 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of HSPE1 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
decreases expression multiple interactions |
ISO |
Cacodylic Acid results in decreased expression of HSPH1 mRNA [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HSPH1 mRNA; OGG1 protein inhibits the reaction [Cacodylic Acid results in decreased expression of HSPH1 mRNA] |
CTD |
PMID:17441966 PMID:34876320 |
|
NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224
|
|
G |
Hvcn1 |
hydrogen voltage-gated channel 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HVCN1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr12:34,341,673...34,370,010
Ensembl chr12:34,335,190...34,370,141
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ICAM1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Icam5 |
intercellular adhesion molecule 5 |
multiple interactions |
ISO |
[Arsenic results in increased abundance of Cacodylic Acid] which affects the expression of ICAM5 mRNA |
CTD |
PMID:28793237 |
|
NCBI chr 8:19,567,390...19,575,588
Ensembl chr 8:19,568,600...19,575,588
|
|
G |
Icos |
inducible T-cell co-stimulator |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ICOS mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 9:62,368,075...62,406,900
Ensembl chr 9:62,383,832...62,405,672
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
increases expression |
EXP |
Cacodylic Acid results in increased expression of IGF1R mRNA |
CTD |
PMID:17481689 |
|
NCBI chr 1:121,549,839...121,838,545
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of IGFBP1 mRNA |
CTD |
PMID:15345372 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
increases expression |
EXP |
Cacodylic Acid results in increased expression of IKBKB protein |
CTD |
PMID:26617437 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Ikzf1 |
IKAROS family zinc finger 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IKZF1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr14:86,255,065...86,340,839
Ensembl chr14:86,255,065...86,342,416
|
|
G |
Il10ra |
interleukin 10 receptor subunit alpha |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL10RA mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:45,563,009...45,578,041
Ensembl chr 8:45,563,137...45,578,061
|
|
G |
Il13ra2 |
interleukin 13 receptor subunit alpha 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL13RA2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr X:111,002,590...111,074,053
Ensembl chr X:111,002,592...111,072,381
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
[Arsenic results in increased abundance of Cacodylic Acid] which affects the expression of IL17A mRNA |
CTD |
PMID:28793237 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il18rap |
interleukin 18 receptor accessory protein |
multiple interactions |
ISO |
[Arsenic results in increased abundance of Cacodylic Acid] which affects the expression of IL18RAP mRNA |
CTD |
PMID:28793237 |
|
NCBI chr 9:42,768,112...42,800,964
Ensembl chr 9:42,768,220...42,800,959
|
|
G |
Il1b |
interleukin 1 beta |
increases secretion |
EXP |
Cacodylic Acid results in increased secretion of IL1B protein |
CTD |
PMID:26617437 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il20rb |
interleukin 20 receptor subunit beta |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL20RB mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:100,979,085...101,010,829
Ensembl chr 8:100,980,383...101,009,942
|
|
G |
Il21r |
interleukin 21 receptor |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL21R mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:180,168,028...180,195,690
Ensembl chr 1:180,168,097...180,195,522
|
|
G |
Il22ra2 |
interleukin 22 receptor subunit alpha 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL22RA2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:14,353,736...14,377,844
Ensembl chr 1:14,364,489...14,377,844
|
|
G |
Il24 |
interleukin 24 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of IL24 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Il27ra |
interleukin 27 receptor subunit alpha |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL27RA mRNA |
CTD |
PMID:34876320 |
|
NCBI chr19:24,109,698...24,121,977
Ensembl chr19:24,109,972...24,121,938
|
|
G |
Il36b |
interleukin 36, beta |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL36B mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 3:7,024,862...7,122,489
Ensembl chr 3:7,021,973...7,031,619
|
|
G |
Il5ra |
interleukin 5 receptor subunit alpha |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL5RA mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 4:139,630,652...139,664,593
Ensembl chr 4:139,632,066...139,668,544
|
|
G |
Il7r |
interleukin 7 receptor |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL7R mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757
|
|
G |
Il9r |
interleukin 9 receptor |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL9R mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:15,431,706...15,444,144
Ensembl chr10:15,431,706...15,441,990
|
|
G |
Inhbe |
inhibin subunit beta E |
decreases expression |
EXP |
Cacodylic Acid results in decreased expression of INHBE mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 7:63,177,558...63,178,983
Ensembl chr 7:63,176,219...63,179,172
|
|
G |
Insig1 |
insulin induced gene 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of INSIG1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Irf1 |
interferon regulatory factor 1 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of IRF1 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166
|
|
G |
Irf4 |
interferon regulatory factor 4 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IRF4 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070
|
|
G |
Irf5 |
interferon regulatory factor 5 |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of IRF5 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr 4:58,127,577...58,140,665
Ensembl chr 4:58,127,640...58,139,267
|
|
G |
Itga10 |
integrin subunit alpha 10 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ITGA10 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:184,182,869...184,202,172
Ensembl chr 2:184,182,869...184,202,172
|
|
G |
Itga8 |
integrin subunit alpha 8 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ITGA8 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr17:75,304,004...75,501,510
Ensembl chr17:75,304,008...75,501,510
|
|
G |
Itgal |
integrin subunit alpha L |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ITGAL mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732
|
|
G |
Itgb1 |
integrin subunit beta 1 |
decreases expression increases expression |
EXP |
Cacodylic Acid results in decreased expression of ITGB1 mRNA Cacodylic Acid results in increased expression of ITGB1 mRNA |
CTD |
PMID:16122865 PMID:17720352 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Itgb6 |
integrin subunit beta 6 |
decreases expression |
EXP |
Cacodylic Acid results in decreased expression of ITGB6 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr 3:45,046,295...45,170,532
Ensembl chr 3:45,048,044...45,121,671
|
|
G |
Itgb8 |
integrin subunit beta 8 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ITGB8 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 6:140,124,997...140,208,254
Ensembl chr 6:140,127,203...140,208,476
|
|
G |
Itih3 |
inter-alpha trypsin inhibitor, heavy chain 3 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of ITIH3 mRNA |
CTD |
PMID:17481689 |
|
NCBI chr16:6,101,922...6,117,154
Ensembl chr16:6,101,930...6,116,924
|
|
G |
Itpripl2 |
ITPRIP like 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ITPRIPL2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:172,801,152...172,803,047
Ensembl chr 1:172,796,849...172,802,950
|
|
G |
Izumo1r |
IZUMO1 receptor, JUNO |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IZUMO1R mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:11,744,383...11,746,872
Ensembl chr 8:11,725,863...11,748,465
|
|
G |
Jag1 |
jagged canonical Notch ligand 1 |
decreases expression |
EXP |
Cacodylic Acid results in decreased expression of JAG1 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr 3:124,406,794...124,442,220
Ensembl chr 3:124,406,794...124,442,209
|
|
G |
Jak2 |
Janus kinase 2 |
decreases expression multiple interactions |
EXP |
Cacodylic Acid results in decreased expression of JAK2 mRNA Cacodylic Acid results in increased expression of and results in increased phosphorylation of JAK2 protein |
CTD |
PMID:17720352 PMID:32890875 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of JUN mRNA |
CTD |
PMID:23192986 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kb15 |
type II keratin Kb15 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of KRT6A mRNA |
CTD |
PMID:32052077 |
|
NCBI chr 7:132,677,994...132,686,634
Ensembl chr 7:132,677,751...132,686,759
|
|
G |
Kcng1 |
potassium voltage-gated channel modifier subfamily G member 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KCNG1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 3:156,960,717...156,992,877
Ensembl chr 3:156,973,156...156,992,635
|
|
G |
Kcnip4 |
potassium voltage-gated channel interacting protein 4 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KCNIP4 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr14:61,380,699...62,531,399
Ensembl chr14:61,381,076...62,530,144
|
|
G |
Kcnj13 |
potassium inwardly-rectifying channel, subfamily J, member 13 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of KCNJ13 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 9:88,063,003...88,071,112
Ensembl chr 9:88,063,003...88,071,112
|
|
G |
Kcnk6 |
potassium two pore domain channel subfamily K member 6 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of KCNK6 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:84,525,613...84,533,948
Ensembl chr 1:84,525,590...84,534,677
|
|
G |
Kdm5d |
lysine demethylase 5D |
increases expression |
ISO |
Cacodylic Acid results in increased expression of KDM5D mRNA |
CTD |
PMID:22246474 |
|
NCBI chr Y:527,069...624,019
Ensembl chr Y:530,401...624,018
|
|
G |
Kif1b |
kinesin family member 1B |
increases expression |
EXP |
Cacodylic Acid results in increased expression of KIF1B mRNA |
CTD |
PMID:17720352 |
|
NCBI chr 5:159,607,697...159,742,778
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Klhl30 |
kelch-like family member 30 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KLHL30 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 9:91,942,443...91,952,756
Ensembl chr 9:91,942,504...91,952,730
|
|
G |
Klhl6 |
kelch-like family member 6 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KLHL6 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr11:80,970,917...81,010,593
Ensembl chr11:80,970,917...81,009,677
|
|
G |
Klrb1a |
killer cell lectin-like receptor subfamily B, member 1A |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KLRB1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 4:161,890,577...161,904,050
Ensembl chr 4:161,890,577...161,961,675
|
|
G |
Kmo |
kynurenine 3-monooxygenase |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KMO mRNA |
CTD |
PMID:34876320 |
|
NCBI chr13:87,557,080...87,589,334
Ensembl chr13:87,557,286...87,588,881
|
|
G |
Kpnb1 |
karyopherin subunit beta 1 |
increases expression multiple interactions |
ISO |
Cacodylic Acid results in increased expression of KPNB1 mRNA OGG1 protein inhibits the reaction [Cacodylic Acid results in increased expression of KPNB1 mRNA] |
CTD |
PMID:17441966 |
|
NCBI chr10:82,145,662...82,174,437
Ensembl chr10:82,145,420...82,174,605
|
|
G |
Krt10 |
keratin 10 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of KRT10 mRNA |
CTD |
PMID:32052077 |
|
NCBI chr10:84,338,695...84,343,279
Ensembl chr10:84,338,706...84,343,701
|
|
G |
Krt12 |
keratin 12 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KRT12 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:84,370,803...84,378,075
Ensembl chr10:84,370,883...84,378,045
|
|
G |
Krt13 |
keratin 13 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of KRT13 mRNA |
CTD |
PMID:32052077 |
|
NCBI chr10:85,052,122...85,056,032
Ensembl chr10:85,051,889...85,056,084
|
|
G |
Krt14 |
keratin 14 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of KRT14 protein |
CTD |
PMID:33211169 |
|
NCBI chr10:85,137,932...85,141,990
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Krt15 |
keratin 15 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of KRT15 mRNA |
CTD |
PMID:32052077 |
|
NCBI chr10:85,066,797...85,070,614
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Krt17 |
keratin 17 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KRT17 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:85,178,673...85,183,392
Ensembl chr10:85,178,675...85,183,392
|
|
G |
Krt18 |
keratin 18 |
decreases expression increases expression |
EXP ISO |
Cacodylic Acid results in decreased expression of KRT18 mRNA Cacodylic Acid results in increased expression of KRT18 mRNA |
CTD |
PMID:17481689 PMID:32052077 |
|
NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
|
|
G |
Krt25 |
keratin 25 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of KRT25 mRNA |
CTD |
PMID:22246474 |
|
NCBI chr10:84,267,600...84,276,312
Ensembl chr10:84,267,399...84,274,965
|
|
G |
Krt27 |
keratin 27 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KRT27 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:84,298,684...84,303,967
Ensembl chr10:84,298,508...84,303,967
|
|
G |
Krt4 |
keratin 4 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of KRT4 mRNA |
CTD |
PMID:32052077 |
|
NCBI chr 7:133,046,067...133,052,027
Ensembl chr 7:133,046,515...133,052,019
|
|
G |
Krt5 |
keratin 5 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of KRT5 mRNA |
CTD |
PMID:32052077 |
|
NCBI chr 7:132,846,355...132,851,986
Ensembl chr 7:132,846,136...132,851,850
|
|
G |
Krt8 |
keratin 8 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of KRT8 mRNA; Cacodylic Acid results in increased expression of KRT8 protein |
CTD |
PMID:32052077 |
|
NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
|
|
G |
Krtap14 |
keratin associated protein 14 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of KRTAP14 mRNA |
CTD |
PMID:22246474 |
|
NCBI chr11:28,126,660...28,127,502
Ensembl chr11:28,126,660...28,127,502
|
|
G |
Krtap8-1 |
keratin associated protein 8-1 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of KRTAP8-1 mRNA |
CTD |
PMID:22246474 |
|
NCBI chr11:28,717,314...28,720,574
Ensembl chr11:28,718,125...28,718,310
|
|
G |
Krtcap2 |
keratinocyte associated protein 2 |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of KRTCAP2 mRNA |
CTD |
PMID:32052077 |
|
NCBI chr 2:174,654,409...174,658,405
Ensembl chr 2:174,654,219...174,658,405
|
|
G |
L3mbtl3 |
L3MBTL histone methyl-lysine binding protein 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of L3MBTL3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:18,988,763...19,089,247
Ensembl chr 1:18,990,618...19,089,263
|
|
G |
Lad1 |
ladinin 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LAD1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr13:47,249,605...47,263,967
Ensembl chr13:47,249,605...47,263,967
|
|
G |
Lars2 |
leucyl-tRNA synthetase 2, mitochondrial |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LARS2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:123,010,271...123,108,957
Ensembl chr 8:123,010,293...123,106,395
|
|
G |
Lax1 |
lymphocyte transmembrane adaptor 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LAX1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr13:45,134,825...45,145,381
Ensembl chr13:45,134,834...45,145,381
|
|
G |
Lbp |
lipopolysaccharide binding protein |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of LBP mRNA |
CTD |
PMID:32052077 |
|
NCBI chr 3:146,953,889...146,981,032
Ensembl chr 3:146,954,015...146,981,586
|
|
G |
Lcp1 |
lymphocyte cytosolic protein 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LCP1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr15:50,443,300...50,544,682
Ensembl chr15:50,488,149...50,544,680
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LDLR mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LEF1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
|
|
G |
Lgals2 |
galectin 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LGALS2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:110,403,171...110,410,046
Ensembl chr 7:110,403,173...110,404,802
|
|
G |
Lgals3 |
galectin 3 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of LGALS3 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025
|
|
G |
Lgals8 |
galectin 8 |
multiple interactions |
ISO |
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of LGALS8 mRNA |
CTD |
PMID:23192986 |
|
NCBI chr17:58,024,652...58,052,764
Ensembl chr17:58,028,105...58,052,764
|
|
G |
Lhfpl2 |
LHFPL tetraspan subfamily member 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of LHFPL2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:25,281,771...25,428,128
Ensembl chr 2:25,281,901...25,427,950
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LIPC mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lman1 |
lectin, mannose-binding, 1 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of LMAN1 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr18:59,508,996...59,530,873
Ensembl chr18:59,508,996...59,530,851
|
|
G |
LOC100359978 |
mCG1038839-like |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV8-12 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 6:136,154,202...136,187,939
|
|
G |
LOC100359993 |
Ighg protein-like |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV5-9 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 6:133,995,951...133,996,562
|
|
G |
LOC102547412 |
zinc finger protein 419-like |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ZFP773 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:66,789,930...66,802,405
Ensembl chr 1:66,788,479...66,802,623
|
|
G |
LOC102548682 |
histone H4-like |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of H4C14 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr17:41,368,743...41,426,735
|
|
G |
LOC108353269 |
Ig kappa chain V-II region 26-10-like |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGKV1-133 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 4:96,968,574...96,969,477
|
|
G |
LOC120099060 |
small nucleolar RNA SNORA69 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of SNORA69 mRNA |
CTD |
PMID:32052077 |
|
NCBI chr20:43,610,465...43,610,598
Ensembl chr20:43,610,465...43,610,598
|
|
G |
LOC681470 |
similar to olfactory receptor 1403 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of OLFR418 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr13:85,723,330...85,724,262
Ensembl chr13:85,719,234...85,724,767
|
|
G |
LOC691141 |
hypothetical protein LOC691141 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of AB124611 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:20,061,494...20,095,705
Ensembl chr 8:20,078,639...20,095,696
|
|
G |
LOC691828 |
uncharacterized LOC691828 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of IGHV4-1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 6:134,212,480...134,234,464
|
|
G |
Lpcat4 |
lysophosphatidylcholine acyltransferase 4 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of LPCAT4 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 3:99,044,729...99,052,963
Ensembl chr 3:99,044,729...99,052,875
|
|
G |
Lpl |
lipoprotein lipase |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of LPL mRNA |
CTD |
PMID:23221991 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lpxn |
leupaxin |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LPXN mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:209,928,297...209,963,085
Ensembl chr 1:209,929,202...209,963,084
|
|
G |
Lrrc31 |
leucine rich repeat containing 31 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LRRC31 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:112,702,844...112,725,431
Ensembl chr 2:112,700,136...112,724,322
|
|
G |
Lrrk2 |
leucine-rich repeat kinase 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LRRK2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:122,826,712...122,987,711
Ensembl chr 7:122,826,696...122,987,703
|
|
G |
Lss |
lanosterol synthase |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LSS mRNA |
CTD |
PMID:34876320 |
|
NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762
|
|
G |
Lta |
lymphotoxin alpha |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LTA mRNA |
CTD |
PMID:34876320 |
|
NCBI chr20:3,618,853...3,621,324
Ensembl chr20:3,618,853...3,620,859
|
|
G |
Ltb |
lymphotoxin beta |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LTB mRNA |
CTD |
PMID:34876320 |
|
NCBI chr20:3,627,536...3,629,381
Ensembl chr20:3,627,537...3,629,381
|
|
G |
Ltb4r2 |
leukotriene B4 receptor 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LTB4R2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr15:29,258,427...29,260,340
Ensembl chr15:29,259,240...29,260,316
|
|
G |
Ly6d |
lymphocyte antigen 6 family member D |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LY6D mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:106,643,225...106,644,733
Ensembl chr 7:106,643,232...106,644,733
|
|
G |
Ly6g6c |
lymphocyte antigen 6 family member G6C |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of LY6G6C mRNA |
CTD |
PMID:34876320 |
|
NCBI chr20:3,753,632...3,757,205
Ensembl chr20:3,753,632...3,758,867
|
|
G |
Ly9 |
lymphocyte antigen 9 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LY9 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr13:84,081,283...84,100,757
Ensembl chr13:84,079,458...84,100,823
|
|
G |
Lyl1 |
LYL1, basic helix-loop-helix family member |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LYL1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr19:23,452,140...23,455,007
Ensembl chr19:23,452,140...23,455,007
|
|
G |
Map3k12 |
mitogen activated protein kinase kinase kinase 12 |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of MAP3K12 mRNA |
CTD |
PMID:17441966 |
|
NCBI chr 7:133,630,267...133,648,464
Ensembl chr 7:133,630,835...133,640,789
|
|
G |
Map3k14 |
mitogen-activated protein kinase kinase kinase 14 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of MAP3K14 mRNA |
CTD |
PMID:17441966 |
|
NCBI chr10:88,165,349...88,215,558
Ensembl chr10:88,165,351...88,215,523
|
|
G |
Map3k19 |
mitogen-activated protein kinase kinase kinase 19 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MAP3K19 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr13:39,300,150...39,343,502
Ensembl chr13:39,300,163...39,343,767
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of MAP3K5 mRNA |
CTD |
PMID:17441966 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Map3k6 |
mitogen-activated protein kinase kinase kinase 6 |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of MAP3K6 mRNA |
CTD |
PMID:17441966 |
|
NCBI chr 5:145,440,126...145,452,213
Ensembl chr 5:145,440,346...145,452,212
|
|
G |
Map3k9 |
mitogen-activated protein kinase kinase kinase 9 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MAP3K9 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 6:101,423,754...101,488,822
Ensembl chr 6:101,430,292...101,488,822
|
|
G |
Map4k1 |
mitogen activated protein kinase kinase kinase kinase 1 |
decreases expression multiple interactions |
ISO |
Cacodylic Acid results in decreased expression of MAP4K1 mRNA [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MAP4K1 mRNA |
CTD |
PMID:17720352 PMID:34876320 |
|
NCBI chr 1:84,270,951...84,292,496
Ensembl chr 1:84,271,069...84,292,493
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO EXP |
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of MAPK1 mRNA Cacodylic Acid results in increased expression of and results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:23192986 PMID:32890875 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk15 |
mitogen-activated protein kinase 15 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MAPK15 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:107,694,907...107,714,640
Ensembl chr 7:107,694,964...107,714,645
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
Cacodylic Acid results in increased expression of and results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:32890875 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases expression decreases expression |
ISO EXP |
Cacodylic Acid results in increased expression of MAPK8 mRNA Cacodylic Acid results in decreased expression of MAPK8 mRNA |
CTD |
PMID:17441966 PMID:17481689 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mas1 |
MAS1 proto-oncogene, G protein-coupled receptor |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of MAS1 mRNA |
CTD |
PMID:22246474 |
|
NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709
|
|
G |
Mbtps1 |
membrane-bound transcription factor peptidase, site 1 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of MBTPS1 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr19:47,561,598...47,612,769
Ensembl chr19:47,561,598...47,612,791
|
|
G |
Mchr1 |
melanin-concentrating hormone receptor 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MCHR1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:112,761,554...112,764,746
Ensembl chr 7:112,761,554...112,764,032
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression multiple interactions |
EXP ISO |
Cacodylic Acid results in increased expression of MDM2 mRNA [sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of MDM2 mRNA |
CTD |
PMID:17481689 PMID:23192986 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mef2c |
myocyte enhancer factor 2C |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MEF2C mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:13,973,299...14,136,065
Ensembl chr 2:13,993,438...14,132,880
|
|
G |
Meioc |
meiosis specific with coiled-coil domain |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MEIOC mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:87,628,807...87,646,485
Ensembl chr10:87,628,875...87,646,752
|
|
G |
Mfap2 |
microfibril associated protein 2 |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of MFAP2 mRNA |
CTD |
PMID:32052077 |
|
NCBI chr 5:153,312,068...153,320,266
Ensembl chr 5:153,314,711...153,320,259
|
|
G |
Mfge8 |
milk fat globule EGF and factor V/VIII domain containing |
increases expression multiple interactions |
EXP ISO |
Cacodylic Acid results in increased expression of MFGE8 mRNA [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MFGE8 mRNA |
CTD |
PMID:16122865 PMID:34876320 |
|
NCBI chr 1:133,064,665...133,080,069
Ensembl chr 1:133,064,665...133,080,073
|
|
G |
Mfsd12 |
major facilitator superfamily domain containing 12 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MFSD12 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:8,345,171...8,354,050
Ensembl chr 7:8,347,314...8,353,988
|
|
G |
Mfsd2b |
major facilitator superfamily domain containing 2B |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MFSD2B mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 6:27,870,182...27,883,768
Ensembl chr 6:27,870,518...27,882,159
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of MGST1 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mir145 |
microRNA 145 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MIR145A mRNA |
CTD |
PMID:34876320 |
|
NCBI chr18:55,099,640...55,099,727
Ensembl chr18:55,099,640...55,099,727
|
|
G |
Mir155hg |
Mir155 host gene |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MIR155HG mRNA |
CTD |
PMID:34876320 |
|
NCBI chr11:23,773,468...23,775,697
|
|
G |
Mir192 |
microRNA 192 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MIR192 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:203,564,946...203,565,055
Ensembl chr 1:203,564,946...203,565,055
|
|
G |
Mkx |
mohawk homeobox |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MKX mRNA |
CTD |
PMID:34876320 |
|
NCBI chr17:55,077,073...55,156,877
Ensembl chr17:55,077,540...55,156,124
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression multiple interactions |
ISO |
Cacodylic Acid results in increased expression of MMP13 mRNA OGG1 protein inhibits the reaction [Cacodylic Acid results in increased expression of MMP13 mRNA] |
CTD |
PMID:17441966 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of MMP14 mRNA |
CTD |
PMID:17441966 |
|
NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
|
|
G |
Mmp17 |
matrix metallopeptidase 17 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of MMP17 mRNA |
CTD |
PMID:17441966 |
|
NCBI chr12:27,074,398...27,099,317
Ensembl chr12:27,074,409...27,099,316
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression multiple interactions |
ISO EXP |
Cacodylic Acid results in increased expression of MMP9 mRNA Cacodylic Acid results in increased expression of MMP9 mRNA; Cacodylic Acid results in increased expression of MMP9 protein monoisoamyl-2,3-dimercaptosuccinate inhibits the reaction [Cacodylic Acid results in increased expression of MMP9 protein] |
CTD |
PMID:17441966 PMID:32474354 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mroh6 |
maestro heat-like repeat family member 6 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MROH6 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:107,566,212...107,576,469
Ensembl chr 7:107,569,554...107,574,173
|
|
G |
Mroh7 |
maestro heat-like repeat family member 7 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MROH7 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:121,463,826...121,509,233
Ensembl chr 5:121,463,827...121,503,755
|
|
G |
Ms4a1 |
membrane spanning 4-domains A1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MS4A1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:207,906,370...207,927,028
Ensembl chr 1:207,906,374...207,918,512
|
|
G |
Ms4a18 |
membrane spanning 4-domains A18 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MS4A18 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:207,644,858...207,662,471
Ensembl chr 1:207,645,780...207,665,793
|
|
G |
Msh2 |
mutS homolog 2 |
decreases expression |
EXP |
Cacodylic Acid results in decreased expression of MSH2 mRNA |
CTD |
PMID:17481689 |
|
NCBI chr 6:6,813,793...6,872,960
Ensembl chr 6:6,813,795...6,872,938
|
|
G |
Msto1 |
misato mitochondrial distribution and morphology regulator 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MSTO1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:174,305,945...174,310,230
Ensembl chr 2:174,301,861...174,310,216
|
|
G |
Mt1 |
metallothionein 1 |
increases expression multiple interactions |
ISO EXP |
Cacodylic Acid results in increased expression of MT1 mRNA [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MT1 mRNA Cacodylic Acid results in increased expression of MT1A mRNA |
CTD |
PMID:16122865 PMID:17441966 PMID:34876320 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
|
|
G |
Mt4 |
metallothionein 4 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MT4 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr19:10,863,813...10,865,909
Ensembl chr19:10,863,813...10,865,909
|
|
G |
Mta1 |
metastasis associated 1 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of MTA1 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 6:132,178,608...132,217,641
Ensembl chr 6:132,178,853...132,217,641
|
|
G |
Mtr |
5-methyltetrahydrofolate-homocysteine methyltransferase |
multiple interactions |
ISO |
[MTR gene SNP affects the susceptibility to Arsenic] which affects the abundance of Cacodylic Acid |
CTD |
PMID:28889078 |
|
NCBI chr17:58,219,998...58,308,560
Ensembl chr17:58,220,071...58,304,822
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MVD mRNA |
CTD |
PMID:34876320 |
|
NCBI chr19:50,496,366...50,506,389
Ensembl chr19:50,496,367...50,507,971
|
|
G |
Mvk |
mevalonate kinase |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MVK mRNA |
CTD |
PMID:34876320 |
|
NCBI chr12:42,141,391...42,158,858
Ensembl chr12:42,141,384...42,158,882
|
|
G |
Mx1 |
MX dynamin like GTPase 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MX1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr11:36,799,659...36,825,209
Ensembl chr11:36,799,660...36,823,507
|
|
G |
Mxd3 |
Max dimerization protein 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MXD3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr17:9,301,430...9,305,156
Ensembl chr17:9,301,399...9,305,157
|
|
G |
Mybl1 |
MYB proto-oncogene like 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MYBL1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:9,582,905...9,618,179
Ensembl chr 5:9,582,934...9,618,183
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of MYC mRNA |
CTD |
PMID:23192986 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myo1g |
myosin IG |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MYO1G mRNA |
CTD |
PMID:34876320 |
|
NCBI chr14:81,386,701...81,401,843
Ensembl chr14:81,386,701...81,401,843
|
|
G |
Myot |
myotilin |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MYOT mRNA |
CTD |
PMID:34876320 |
|
NCBI chr18:36,705,244...36,724,849
Ensembl chr18:36,705,314...36,724,841
|
|
G |
Mzb1 |
marginal zone B and B1 cell-specific protein |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MZB1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr18:27,238,999...27,241,060
Ensembl chr18:27,239,001...27,241,094
|
|
G |
Naaladl1 |
N-acetylated alpha-linked acidic dipeptidase-like 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NAALADL1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:203,400,632...203,414,195
Ensembl chr 1:203,400,631...203,414,195
|
|
G |
Napsa |
napsin A aspartic peptidase |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NAPSA mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:95,064,726...95,077,101
Ensembl chr 1:95,064,900...95,077,094
|
|
G |
Nbl1 |
NBL1, DAN family BMP antagonist |
increases expression |
EXP |
Cacodylic Acid results in increased expression of NBL1 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 5:151,318,752...151,329,948
Ensembl chr 5:151,318,754...151,338,719
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NCF1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ncmap |
noncompact myelin associated protein |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NCMAP mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:147,608,042...147,623,266
Ensembl chr 5:147,610,677...147,618,775
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NDRG1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880
|
|
G |
Ndst3 |
N-deacetylase and N-sulfotransferase 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NDST3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:211,702,728...211,868,159
Ensembl chr 2:211,704,898...211,854,584
|
|
G |
Neb |
nebulin |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NEB mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 3:36,613,677...36,811,618
Ensembl chr 3:36,613,716...36,811,574
|
|
G |
Nectin1 |
nectin cell adhesion molecule 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NECTIN1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:44,101,776...44,164,863
Ensembl chr 8:44,101,776...44,189,787
|
|
G |
Neo1 |
neogenin 1 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of NEO1 mRNA |
CTD |
PMID:22246474 |
|
NCBI chr 8:59,273,860...59,426,486
Ensembl chr 8:59,275,569...59,430,348
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
[Cacodylic Acid results in increased abundance of Arsenic] which results in increased expression of and affects the localization of NFE2L2 protein; [Cacodylic Acid results in increased abundance of Arsenic] which results in increased expression of NFE2L2 protein; Cacodylic Acid results in increased expression of and affects the localization of NFE2L2 protein; NFE2L2 mutant form inhibits the reaction [Cacodylic Acid results in increased expression of NQO1 protein] |
CTD |
PMID:24161444 PMID:33434570 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfia |
nuclear factor I/A |
increases expression |
EXP |
Cacodylic Acid results in increased expression of NFIA mRNA |
CTD |
PMID:17720352 |
|
NCBI chr 5:112,436,655...112,781,878
Ensembl chr 5:112,436,644...112,775,885
|
|
G |
Nfic |
nuclear factor I/C |
increases expression |
EXP |
Cacodylic Acid results in increased expression of NFIC mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 7:8,278,210...8,309,936
Ensembl chr 7:8,253,361...8,309,936
|
|
G |
Nfil3 |
nuclear factor, interleukin 3 regulated |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NFIL3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr17:12,280,499...12,295,728
Ensembl chr17:12,280,484...12,295,858
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions increases expression |
ISO EXP |
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of NFKB1 mRNA Cacodylic Acid results in increased expression of NFKB1 mRNA Cacodylic Acid results in increased expression of and affects the localization of NFKB1 protein |
CTD |
PMID:23192986 PMID:26617437 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Niban3 |
niban apoptosis regulator 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NIBAN3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr16:18,307,122...18,318,589
Ensembl chr16:18,307,221...18,318,585
|
|
G |
Ninj1 |
ninjurin 1 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of NINJ1 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr17:15,452,804...15,461,684
Ensembl chr17:15,452,813...15,461,704
|
|
G |
Nipal4 |
NIPA-like domain containing 4 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NIPAL4 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:30,583,926...30,600,640
Ensembl chr10:30,583,926...30,600,640
|
|
G |
Nlrp9 |
NLR family, pyrin domain containing 9 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NLRP9B mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:68,291,180...68,341,512
Ensembl chr 1:68,291,180...68,341,512
|
|
G |
Nmu |
neuromedin U |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NMU mRNA |
CTD |
PMID:34876320 |
|
NCBI chr14:31,844,564...31,872,196
Ensembl chr14:31,844,728...31,872,192
|
|
G |
Noct |
nocturnin |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NOCT mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:135,271,189...135,291,407
Ensembl chr 2:135,271,189...135,291,400
|
|
G |
Nod2 |
nucleotide-binding oligomerization domain containing 2 |
multiple interactions |
ISO |
[Arsenic results in increased abundance of Cacodylic Acid] which affects the expression of NOD2 mRNA |
CTD |
PMID:28793237 |
|
NCBI chr19:18,379,720...18,422,817
Ensembl chr19:18,382,439...18,417,177
|
|
G |
Notch1 |
notch receptor 1 |
affects expression |
EXP |
Cacodylic Acid affects the expression of NOTCH1 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Notch3 |
notch receptor 3 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of NOTCH3 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr 7:11,132,984...11,184,025
Ensembl chr 7:11,133,706...11,184,025
|
|
G |
Npas4 |
neuronal PAS domain protein 4 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NPAS4 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:202,281,260...202,298,681
Ensembl chr 1:202,281,958...202,286,724
|
|
G |
Npffr1 |
neuropeptide FF receptor 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NPFFR1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr20:29,539,795...29,573,951
Ensembl chr20:29,539,795...29,571,196
|
|
G |
Nppa |
natriuretic peptide A |
increases expression |
ISO |
Cacodylic Acid results in increased expression of NPPA mRNA |
CTD |
PMID:32052077 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Npy5r |
neuropeptide Y receptor Y5 |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of NPY5R mRNA |
CTD |
PMID:22246474 |
|
NCBI chr16:23,055,427...23,063,384
Ensembl chr16:23,055,427...23,063,382
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
ISO |
Cacodylic Acid results in increased expression of NQO1 mRNA Cacodylic Acid promotes the reaction [sulforaphane results in increased expression of and results in increased activity of NQO1 protein]; Cacodylic Acid promotes the reaction [sulforaphane results in increased expression of NQO1 mRNA]; Cacodylic Acid promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of and results in increased activity of NQO1 protein]; Cacodylic Acid promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]; Cacodylic Acid results in increased expression of and results in increased activity of NQO1 protein; NFE2L2 mutant form inhibits the reaction [Cacodylic Acid results in increased expression of NQO1 protein] |
CTD |
PMID:15345372 PMID:24161444 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NR0B2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nrg1 |
neuregulin 1 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of NRG1 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr16:59,250,658...60,303,024
Ensembl chr16:59,250,854...60,296,884
|
|
G |
Nt5e |
5' nucleotidase, ecto |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NT5E mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881
|
|
G |
Nuggc |
nuclear GTPase, germinal center associated |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NUGGC mRNA |
CTD |
PMID:34876320 |
|
NCBI chr15:39,821,851...39,866,122
Ensembl chr15:39,821,855...39,866,122
|
|
G |
Nxpe3 |
neurexophilin and PC-esterase domain family, member 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NXPE3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr11:44,726,905...44,777,694
Ensembl chr11:44,727,069...44,777,694
|
|
G |
Nxpe4 |
neurexophilin and PC-esterase domain family member 4 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NXPE4 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:48,502,697...48,744,101
Ensembl chr 8:48,722,440...48,744,100
|
|
G |
Nyx |
nyctalopin |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NYX mRNA |
CTD |
PMID:34876320 |
|
NCBI chr X:9,280,864...9,301,900
Ensembl chr X:9,280,864...9,301,900
|
|
G |
Oas2 |
2'-5' oligoadenylate synthetase 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of OAS2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr12:35,802,824...35,830,778
Ensembl chr12:35,806,759...35,829,371
|
|
G |
Oaz1 |
ornithine decarboxylase antizyme 1 |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of OAZ1 mRNA |
CTD |
PMID:17441966 |
|
NCBI chr 7:8,883,855...8,886,315
Ensembl chr 7:8,883,851...8,886,310
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
multiple interactions increases expression |
ISO EXP |
OGG1 protein inhibits the reaction [Cacodylic Acid results in decreased expression of HSPA1B mRNA]; OGG1 protein inhibits the reaction [Cacodylic Acid results in decreased expression of HSPA4L mRNA]; OGG1 protein inhibits the reaction [Cacodylic Acid results in decreased expression of HSPA8 mRNA]; OGG1 protein inhibits the reaction [Cacodylic Acid results in decreased expression of HSPB1 mRNA]; OGG1 protein inhibits the reaction [Cacodylic Acid results in decreased expression of HSPH1 mRNA]; OGG1 protein inhibits the reaction [Cacodylic Acid results in increased expression of AOC3 mRNA]; OGG1 protein inhibits the reaction [Cacodylic Acid results in increased expression of CCNC mRNA]; OGG1 protein inhibits the reaction [Cacodylic Acid results in increased expression of CDH4 mRNA]; OGG1 protein inhibits the reaction [Cacodylic Acid results in increased expression of CFD mRNA]; OGG1 protein inhibits the reaction [Cacodylic Acid results in increased expression of CYP7B1 mRNA]; OGG1 protein inhibits the reaction [Cacodylic Acid results in increased expression of KPNB1 mRNA]; OGG1 protein inhibits the reaction [Cacodylic Acid results in increased expression of MMP13 mRNA] Cacodylic Acid results in increased expression of OGG1 mRNA |
CTD |
PMID:17441966 PMID:17481689 |
|
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
|
|
G |
Osr2 |
odd-skipped related transciption factor 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of OSR2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:66,487,841...66,495,003
Ensembl chr 7:66,487,839...66,495,224
|
|
G |
Oxct2a |
3-oxoacid CoA transferase 2A |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of OXCT2A mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:135,600,812...135,603,045
Ensembl chr 5:135,591,507...135,602,569
|
|
G |
P2ry10 |
P2Y receptor family member 10 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of P2RY10 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr X:72,121,558...72,207,174
Ensembl chr X:72,111,264...72,212,265
|
|
G |
P4ha1 |
prolyl 4-hydroxylase subunit alpha 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of P4HA1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr20:27,302,046...27,352,098
Ensembl chr20:27,302,141...27,352,786
|
|
G |
Pacsin2 |
protein kinase C and casein kinase substrate in neurons 2 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of PACSIN2 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 7:114,505,525...114,599,087
Ensembl chr 7:114,505,152...114,598,546
|
|
G |
Pak2 |
p21 (RAC1) activated kinase 2 |
decreases expression |
EXP |
Cacodylic Acid results in decreased expression of PAK2 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr11:68,708,070...68,766,622
Ensembl chr11:68,707,969...68,768,816
|
|
G |
Pappa1 |
pappalysin 1 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of PAPPA mRNA |
CTD |
PMID:32052077 |
|
NCBI chr 5:78,497,660...78,735,873
Ensembl chr 5:78,498,300...78,730,666
|
|
G |
Parvg |
parvin, gamma |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PARVG mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:115,456,183...115,475,707
Ensembl chr 7:115,456,209...115,475,104
|
|
G |
Pax5 |
paired box 5 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PAX5 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:58,763,334...58,945,719
Ensembl chr 5:58,765,036...58,944,326
|
|
G |
Pax6 |
paired box 6 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PAX6 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014
|
|
G |
Pcdh1 |
protocadherin 1 |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of PCDH1 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr18:30,011,692...30,039,679
Ensembl chr18:30,013,185...30,039,318
|
|
G |
Pcdh15 |
protocadherin related 15 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PCDH15 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr20:13,997,094...15,496,446
Ensembl chr20:13,963,565...15,494,719
|
|
G |
Pcdhgb1 |
protocadherin gamma subfamily B, 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PCDHGB1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr18:29,501,739...29,508,024
|
|
G |
Pced1b |
PC-esterase domain containing 1B |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PCED1B mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:128,394,388...128,528,231
Ensembl chr 7:128,391,319...128,528,231
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of PCK1 mRNA |
CTD |
PMID:17441966 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pcna |
proliferating cell nuclear antigen |
increases expression |
EXP |
Cacodylic Acid results in increased expression of PCNA mRNA; Cacodylic Acid results in increased expression of PCNA protein |
CTD |
PMID:17481689 PMID:24832369 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pcsk9 |
proprotein convertase subtilisin/kexin type 9 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PCSK9 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688
|
|
G |
Pdcd2 |
programmed cell death 2 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of PDCD2 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 1:56,484,947...56,490,437
Ensembl chr 1:56,463,931...56,490,437
|
|
G |
Pde3b |
phosphodiesterase 3B |
decreases expression |
EXP |
Cacodylic Acid results in decreased expression of PDE3B mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 1:168,606,762...168,770,078
Ensembl chr 1:168,607,022...168,769,334
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
decreases expression |
EXP |
Cacodylic Acid results in decreased expression of PDK4 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Per1 |
period circadian regulator 1 |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of PER1 mRNA |
CTD |
PMID:32052077 |
|
NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431
|
|
G |
Phex |
phosphate regulating endopeptidase homolog, X-linked |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of PHEX mRNA |
CTD |
PMID:32052077 |
|
NCBI chr X:37,607,553...37,856,183
Ensembl chr X:37,610,760...37,854,469
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PHLDA1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:46,967,433...46,969,637
Ensembl chr 7:46,967,409...46,969,861
|
|
G |
Pitx1 |
paired-like homeodomain 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PITX1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr17:8,794,134...8,800,292
Ensembl chr17:8,794,134...8,800,291
|
|
G |
Pla2g1b |
phospholipase A2 group IB |
decreases expression |
ISO |
Cacodylic Acid results in decreased expression of PLA2G1B mRNA |
CTD |
PMID:32052077 |
|
NCBI chr12:41,142,193...41,151,967
Ensembl chr12:41,142,200...41,153,226
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLA2G2A mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
|
|
G |
Pla2g2d |
phospholipase A2, group IID |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PLA2G2D mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:151,016,010...151,022,531
Ensembl chr 5:151,018,870...151,022,525
|
|
G |
Pla2g4f |
phospholipase A2, group IVF |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PLA2G4F mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 3:107,249,053...107,266,201
Ensembl chr 3:107,250,075...107,264,689
|
|
G |
Pla2g7 |
phospholipase A2 group VII |
increases expression |
ISO |
Cacodylic Acid results in increased expression of PLA2G7 mRNA |
CTD |
PMID:17441966 |
|
NCBI chr 9:17,362,214...17,404,476
Ensembl chr 9:17,362,225...17,404,476
|
|
G |
Plau |
plasminogen activator, urokinase |
multiple interactions |
ISO |
[Arsenic results in increased abundance of Cacodylic Acid] which affects the expression of PLAU mRNA |
CTD |
PMID:28793237 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLAUR mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:80,053,441...80,068,384
Ensembl chr 1:80,050,324...80,068,595
|
|
G |
Plb1 |
phospholipase B1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLB1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 6:24,087,051...24,227,167
Ensembl chr 6:24,089,214...24,210,117
|
|
G |
Pld2 |
phospholipase D2 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of PLD2 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr10:55,256,326...55,274,192
Ensembl chr10:55,256,359...55,272,808
|
|
G |
Pld4 |
phospholipase D family, member 4 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PLD4 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 6:131,818,860...131,827,457
Ensembl chr 6:131,818,860...131,826,376
|
|
G |
Plek |
pleckstrin |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PLEK mRNA |
CTD |
PMID:34876320 |
|
NCBI chr14:91,397,015...91,429,693
Ensembl chr14:91,397,019...91,454,131
|
|
G |
Plekhg4 |
pleckstrin homology and RhoGEF domain containing G4 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLEKHG4 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr19:33,251,788...33,266,490
Ensembl chr19:33,249,706...33,266,357
|
|
G |
Plet1 |
placenta expressed transcript 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLET1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:50,842,210...50,854,015
Ensembl chr 8:50,841,854...50,853,659
|
|
G |
Plk3 |
polo-like kinase 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLK3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 5:130,607,142...130,612,317
Ensembl chr 5:130,607,142...130,612,317
|
|
G |
Plxnc1 |
plexin C1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PLXNC1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:29,390,038...29,543,985
Ensembl chr 7:29,390,048...29,543,779
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PMAIP1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr18:59,986,187...59,990,174
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Pnpla1 |
patatin-like phospholipase domain containing 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PNPLA1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr20:6,918,446...6,951,650
Ensembl chr20:6,917,931...6,952,375
|
|
G |
Pnpla3 |
patatin-like phospholipase domain containing 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PNPLA3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:115,293,538...115,314,077
Ensembl chr 7:115,293,538...115,314,077
|
|
G |
Pola1 |
DNA polymerase alpha 1, catalytic subunit |
increases expression |
ISO |
Cacodylic Acid results in increased expression of POLA1 mRNA |
CTD |
PMID:17441966 |
|
NCBI chr X:58,034,617...58,348,612
Ensembl chr X:58,034,619...58,348,536
|
|
G |
Pold1 |
DNA polymerase delta 1, catalytic subunit |
increases expression |
EXP |
Cacodylic Acid results in increased expression of POLD1 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr 1:95,025,462...95,041,559
Ensembl chr 1:95,025,499...95,036,465
|
|
G |
Pold4 |
DNA polymerase delta 4, accessory subunit |
increases expression |
ISO |
Cacodylic Acid results in increased expression of POLD4 mRNA |
CTD |
PMID:17441966 |
|
NCBI chr 1:201,526,591...201,528,406
Ensembl chr 1:201,526,665...201,528,401
|
|
G |
Pole2 |
DNA polymerase epsilon 2, accessory subunit |
increases expression |
ISO |
Cacodylic Acid results in increased expression of POLE2 mRNA |
CTD |
PMID:17441966 |
|
NCBI chr 6:87,674,702...87,712,723
Ensembl chr 6:87,674,702...87,699,305
|
|
G |
Polg |
DNA polymerase gamma, catalytic subunit |
increases expression |
ISO |
Cacodylic Acid results in increased expression of POLG mRNA |
CTD |
PMID:17441966 |
|
NCBI chr 1:133,382,764...133,399,578
Ensembl chr 1:133,382,766...133,398,567
|
|
G |
Poli |
DNA polymerase iota |
increases expression |
ISO |
Cacodylic Acid results in increased expression of POLI mRNA |
CTD |
PMID:17441966 |
|
NCBI chr18:64,116,774...64,134,373
Ensembl chr18:64,116,774...64,163,418
|
|
G |
Pon1 |
paraoxonase 1 |
increases expression |
ISO |
Cacodylic Acid results in increased expression of PON1 mRNA |
CTD |
PMID:32052077 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Pou2af1 |
POU class 2 homeobox associating factor 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of POU2AF1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:51,521,813...51,548,819
Ensembl chr 8:51,474,015...51,548,819
|
|
G |
Pou2f2 |
POU class 2 homeobox 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of POU2F2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:80,682,330...80,769,756
Ensembl chr 1:80,685,741...80,724,261
|
|
G |
Pou3f1 |
POU class 3 homeobox 1 |
decreases expression |
EXP |
Cacodylic Acid results in decreased expression of POU3F1 mRNA |
CTD |
PMID:17720352 |
|
NCBI chr 5:136,910,391...136,913,371
Ensembl chr 5:136,910,391...136,913,371
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression multiple interactions |
ISO |
Cacodylic Acid results in decreased expression of PPARG mRNA [Arsenic results in increased abundance of Cacodylic Acid] which affects the expression of PPARG mRNA |
CTD |
PMID:23221991 PMID:28793237 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp1r16b |
protein phosphatase 1, regulatory subunit 16B |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PPP1R16B mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 3:147,323,652...147,419,658
Ensembl chr 3:147,324,126...147,418,937
|
|
G |
Prdx2 |
peroxiredoxin 2 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of PRDX2 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr19:23,180,927...23,186,217
Ensembl chr19:23,180,930...23,186,194
|
|
G |
Preb |
prolactin regulatory element binding |
increases expression |
EXP |
Cacodylic Acid results in increased expression of PREB mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 6:25,418,805...25,422,594
Ensembl chr 6:25,418,776...25,422,590
|
|
G |
Prkca |
protein kinase C, alpha |
increases expression |
EXP |
Cacodylic Acid results in increased expression of PRKCA mRNA |
CTD |
PMID:17481689 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkcg |
protein kinase C, gamma |
increases expression |
EXP |
Cacodylic Acid results in increased expression of PRKCG mRNA |
CTD |
PMID:17481689 |
|
NCBI chr 1:65,832,851...65,860,676
Ensembl chr 1:65,832,855...65,859,384
|
|
G |
Prkcz |
protein kinase C, zeta |
increases expression |
EXP |
Cacodylic Acid results in increased expression of PRKCZ mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 5:165,817,786...165,930,386
Ensembl chr 5:165,819,466...165,930,367
|
|
G |
Prr5l |
proline rich 5 like |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PRR5L mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 3:88,001,951...88,173,532
Ensembl chr 3:88,003,617...88,082,763
|
|
G |
Prss16 |
serine protease 16 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PRSS16 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr17:42,514,306...42,521,885
Ensembl chr17:42,514,306...42,521,884
|
|
G |
Psca |
prostate stem cell antigen |
increases expression |
ISO |
Cacodylic Acid results in increased expression of PSCA mRNA |
CTD |
PMID:32052077 |
|
NCBI chr 7:106,598,203...106,603,114
Ensembl chr 7:106,595,284...106,609,746
|
|
G |
Ptgfr |
prostaglandin F receptor |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PTGFR mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:240,731,185...240,766,674
Ensembl chr 2:240,733,375...240,765,650
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of PTGS2 mRNA; Cacodylic Acid results in increased expression of PTGS2 protein |
CTD |
PMID:12151359 PMID:24832369 PMID:32890875 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
increases expression |
EXP |
Cacodylic Acid results in increased expression of PTK2B mRNA |
CTD |
PMID:16122865 |
|
NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282
|
|
G |
Ptpn7 |
protein tyrosine phosphatase, non-receptor type 7 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PTPN7 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr13:46,570,904...46,584,048
Ensembl chr13:46,571,712...46,583,308
|
|
G |
Ptprc |
protein tyrosine phosphatase, receptor type, C |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PTPRC mRNA |
CTD |
PMID:34876320 |
|
NCBI chr13:49,596,193...49,708,283
Ensembl chr13:49,596,193...49,708,692
|
|
G |
Ptprcap |
protein tyrosine phosphatase, receptor type, C-associated protein |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PTPRCAP mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:201,449,133...201,451,293
Ensembl chr 1:201,449,113...201,451,288
|
|
G |
Qrfpr |
pyroglutamylated RFamide peptide receptor |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of QRFPR mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 2:119,053,511...119,096,792
Ensembl chr 2:119,053,511...119,096,792
|
|
G |
Rab10 |
RAB10, member RAS oncogene family |
increases expression |
EXP |
Cacodylic Acid results in increased expression of RAB10 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 6:26,267,081...26,319,739
Ensembl chr 6:26,266,859...26,320,193
|
|
G |
Rab14 |
RAB14, member RAS oncogene family |
increases expression decreases expression |
EXP |
Cacodylic Acid results in increased expression of RAB14 mRNA Cacodylic Acid results in decreased expression of RAB14 mRNA |
CTD |
PMID:16122865 PMID:17720352 |
|
NCBI chr 3:18,501,953...18,523,253
Ensembl chr 3:18,501,963...18,523,172
|
|
G |
Rab1a |
RAB1A, member RAS oncogene family |
increases expression |
EXP |
Cacodylic Acid results in increased expression of RAB1A mRNA |
CTD |
PMID:16122865 |
|
NCBI chr14:94,422,219...94,448,799
Ensembl chr14:94,415,275...94,448,248
|
|
G |
Rab33a |
RAB33A, member RAS oncogene family |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RAB33A mRNA |
CTD |
PMID:34876320 |
|
NCBI chr X:127,694,219...127,706,378
Ensembl chr X:127,694,964...127,706,378
|
|
G |
Rab7a |
RAB7A, member RAS oncogene family |
decreases expression increases expression |
ISO EXP |
Cacodylic Acid results in decreased expression of RAB7 mRNA Cacodylic Acid results in increased expression of RAB7 mRNA |
CTD |
PMID:16122865 PMID:17720352 |
|
NCBI chr 4:120,461,966...120,510,756
Ensembl chr 4:120,461,963...120,506,889
|
|
G |
Rad51c |
RAD51 paralog C |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RAD51C mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:72,205,032...72,231,643
Ensembl chr10:72,205,032...72,231,248
|
|
G |
Radx |
RPA1 related single stranded DNA binding protein, X-linked |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RADX mRNA |
CTD |
PMID:34876320 |
|
NCBI chr X:103,089,284...103,176,840
Ensembl chr X:103,089,284...103,176,838
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions increases expression |
ISO EXP |
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of RAF1 mRNA Cacodylic Acid results in increased expression of RAF1 protein |
CTD |
PMID:23192986 PMID:32890875 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Ralgds |
ral guanine nucleotide dissociation stimulator |
increases expression |
EXP |
Cacodylic Acid results in increased expression of RALGDS mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 3:11,839,686...11,880,059
Ensembl chr 3:11,839,416...11,880,059
|
|
G |
Ramp1 |
receptor activity modifying protein 1 |
increases expression |
EXP |
Cacodylic Acid results in increased expression of RAMP1 mRNA |
CTD |
PMID:16122865 |
|
NCBI chr 9:91,765,481...91,816,152
Ensembl chr 9:91,781,285...91,816,151
|
|
G |
Ran |
RAN, member RAS oncogene family |
increases expression |
EXP |
Cacodylic Acid results in increased expression of RAN mRNA |
CTD |
PMID:16122865 |
|
NCBI chr12:27,674,049...27,678,598
Ensembl chr12:27,674,050...27,678,276
|
|
G |
Rasal3 |
RAS protein activator like 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RASAL3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:11,396,090...11,411,349
Ensembl chr 7:11,396,090...11,411,465
|
|
G |
Rasd1 |
ras related dexamethasone induced 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RASD1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr10:44,766,451...44,775,773
Ensembl chr10:44,766,455...44,768,186
|
|
G |
Rasgrp3 |
RAS guanyl releasing protein 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RASGRP3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 6:19,895,366...19,993,945
Ensembl chr 6:19,895,390...19,958,578
|
|
G |
Rasl11a |
RAS-like family 11 member A |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RASL11A mRNA |
CTD |
PMID:34876320 |
|
NCBI chr12:8,258,148...8,262,576
Ensembl chr12:8,258,159...8,262,576
|
|
G |
Rec114 |
REC114 meiotic recombination protein |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of REC114 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:59,063,352...59,221,439
Ensembl chr 8:59,063,352...59,149,887
|
|
G |
Rec8 |
REC8 meiotic recombination protein |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of REC8 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr15:29,109,862...29,117,327
Ensembl chr15:29,109,863...29,117,326
|
|
G |
Reep6 |
receptor accessory protein 6 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of REEP6 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 7:9,373,927...9,380,845
Ensembl chr 7:9,373,927...9,380,597
|
|
G |
Reg3b |
regenerating family member 3 beta |
decreases expression multiple interactions |
EXP ISO |
Cacodylic Acid results in decreased expression of REG3B mRNA [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of REG3B mRNA |
CTD |
PMID:16122865 PMID:34876320 |
|
NCBI chr 4:110,861,775...110,865,015
Ensembl chr 4:110,861,775...110,865,015
|
|
G |
Reg3g |
regenerating family member 3 gamma |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of REG3G mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 4:110,922,805...110,927,803
Ensembl chr 4:110,924,168...110,926,723
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of RELA mRNA |
CTD |
PMID:23192986 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rell2 |
RELT-like 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RELL2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr18:29,789,996...29,793,986
Ensembl chr18:29,790,415...29,793,986
|
|
G |
Rgl3 |
ral guanine nucleotide dissociation stimulator-like 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RGL3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 8:20,500,846...20,520,471
Ensembl chr 8:20,500,846...20,520,471
|
|
G |
Rgs1 |
regulator of G-protein signaling 1 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RGS1 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr13:56,018,529...56,022,939
Ensembl chr13:56,018,554...56,022,984
|
|
G |
Rhoh |
ras homolog family member H |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RHOH mRNA |
CTD |
PMID:34876320 |
|
NCBI chr14:42,341,135...42,371,971
Ensembl chr14:42,337,751...42,386,369
|
|
G |
Ripk3 |
receptor-interacting serine-threonine kinase 3 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RIPK3 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr15:29,283,153...29,292,107
Ensembl chr15:29,283,145...29,292,121
|
|
G |
Ripor2 |
RHO family interacting cell polarization regulator 2 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RIPOR2 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr17:40,323,867...40,547,482
Ensembl chr17:40,323,867...40,548,092
|
|
G |
Rnase6 |
ribonuclease A family member k6 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RNASE6 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr15:24,354,305...24,357,289
Ensembl chr15:24,354,303...24,357,328
|
|
G |
Rnf225 |
ring finger protein 225 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RNF225 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 1:73,543,598...73,546,269
Ensembl chr 1:73,543,598...73,546,269
|
|
G |
Rnf24 |
ring finger protein 24 |
multiple interactions |
ISO |
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RNF24 mRNA |
CTD |
PMID:34876320 |
|
NCBI chr 3:118,525,349...118,526,312
Ensembl chr 3:118,525,349...118,541,080
|
|
G |
Rock1 |
Rho-associated coiled-coil containing protein kinase 1 |
decreases expression |
| |